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The synthesis of BRL-37959 has previously been reported. As an NSAID, the compound 
was tested for and found that it had very low gastric irritancy. Commercially available 
NSAIDs are non-selective COX inhibitors that enhance the risk of gastric, duodenal 
mucosal injury or erosions and ulcer problems as well as lead to nephrotoxicity. The  
COX-2 selective inhibitor Celecoxib (Celebrex) increases the risk of serious 
cardiovascular (CV) thrombotic events, myocardial infarction and stroke as well as 
increased nephrotoxicity. COX inhibitors are active against inflammation, pain, fever and 
different types of cancers.   Considering the enormous potential benefits and side effects 
of non-selective COX inhibitors and selective COX-2 inhibitor. Our research goal was to 
iii 
 
find a COX inhibitor that binds with both COX-1 and COX-2 in such a ratio that it would 
be a safer drug. Another aim was to develop a synthesis method of the target inhibitor 
that will be simple, cost-effective and ensure high yield. Benzofuran is an important 
building block of BRL- 37959. In Dr. Hossain's lab, Matt Dudley had developed a novel, 
unprecedented, one pot procedure to synthesize various benzofuran derivatives. We 
have followed the efficient, large scale potential, high yield and simple process to 
synthesize benzofuran. Based on the synthesis of benzofuran, we have developed a short 
and more cost-effective procedure for the synthesis of BRL-37959. The older method was 
tedious and resulted in very low yields (≤ 5%). This new method is simple and uses 
inexpensive starting materials, as well as giving high overall yields (62%). In enzyme 
screening, we found that BRL-37959 selectively binds with COX-1. We followed our 
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Introduction   
Benzofuran, an important class of heterocyclic compound is present in as a core moiety 
in different natural products and pharmaceuticals as well as polymers.  Many derivatives 
of benzofuran of natural and synthetic sources have biological properties such as anti-
inflammatory, antimicrobial, antifungal, antihyperglycemic, analgesic, antiparasitic, and 
antitumor activities.1-7 Several Non-steroidal anti-inflammation drugs (NSAIDs) possess 
the benzofuran scaffold such as morphine, codeine, oxycodone, BRL-37959, naltrexone 
and naloxone (Figure-1).  
 
1.2. NSAIDs  
NSAIDs are used mostly in the treatment of inflammation, pain, and edema, as well as of 
osteoarthritis, rheumatoid arthritis, and musculoskeletal disorders. Because of selectivity 
to cyclooxygenase (COX) enzymes, all available NSAIDs are classified into two 
categories. (Table-1)   
1.2.1 NASIDs and their Function 
NSAIDs block the active sites of both COX1 and COX2 and thus prevents prostaglandin 
formation. Almost all NSAIDs are non-selective and bind to both enzymes, but relieve 
patients from inflammation, pain, and fever as well as create gastric irritancy, ulcers and 
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renal failure over long term use. The COX, non-selective NSAIDs inhibit the secretion 
of prostaglandins in the gastrointestinal mucosa and produce gastroduodenitis, 
gastric ulcers, and digestive bleeding. Since non-selective NSAIDs block COX-1 in 
the gastrointestinal mucosa and they consequently inhibit the production of 
prostacyclin, PGE2, and PGD2 in the stomach8-13 but cause adverse side effects. 
These effects prostaglandins act as cytoprotective agents of the gastrointestinal 
mucosa; they inhibit the acid secretion by the stomach, increase the blood flow and 
the production of the protective mucus. However, COX1 enzymes releases 
prostaglandins, prostacyclin, PGE2 and PGD2 in kidneys, dilate the vasculature, 
reduce the renal vascular resistance and boost the organ perfusion(Figure-2).14 
These effects lead to the redistribution of the blood flow from the renal cortex to the 
nephrons in the intramedullary region.15,16The inhibition of these mechanisms tends 
to decrease the total renal perfusion and rearrange the blood flow to the cortex; a 






Indomethacin (Indocin) Valdecoxib 
Ibuprofen (Advil, Motrin) Parecoxib 
Naproxen (Aleve, Naprosyn) Celecoxib 




Piroxicam (Feldene) Selectives (COX-2) 
β- Piroxicam (Cycladol) COXIBs 
Meloxicam (Movatec) Rofecoxib 
  Valdecoxib 
Ketoprofen (Profenid) Parecoxib 
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progression that ends in severe renal vasoconstriction, medullary ischemia and, 
under certain conditions, acute kidney failure.COX1 enzyme releases thromboxane 
that aggregates platelet and COX2 enzyme synthesizes prostaglandins that act as a 
vasodilators. This prostaglandin keeps blood vessel free from clogging. There is a 
dynamic balance between the platelet aggregation and vasodilation. The selective 
COX-2 inhibition in the heart creates a tendency to thrombosis, due to the shift in the 
pro-thrombotic/anti-thrombotic balance on the endothelial surface and damage of the 
protecting effect of the up- regulation of COX-2 in cardiac ischemia and myocardial 
infarction18-20 (Figure- 3). 
 
Figure 2 - Representation of the effects related to COX-1 inhibition. COX - cyclooxygenase; PG - 
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Figure 3 - Schematic representation of the effects related to COX-2 inhibition. COX - cyclooxygenase; PG - 
prostaglandin; TX - thromboxane; GI - gastrointestinal; RA - renal arteriole; GBF - glomerular blood flow; 
AMI - acute myocardial infarction; HF - heart failure; KF - kidney failure 
 
Celebrex, the only COX2 selective inhibitor is available on the market, because of 
cardiovascular problems, the FDA applied restriction on its use. Moreover, at present, 
there are no non-opioids safe drugs for inflammation and pain. 
Opioids are a group of medications that include the illegal drug heroin, synthetic opioids 
such as fentanyl, and prescription pain relief drugs such as oxycodone (OxyContin®), 
hydrocodone (Vicodin®), codeine, morphine, and many others. These drugs are 
chemically associated and act on opioid receptors on nerve cells in the body and brain. 
Chronic pain affects about 100 million people in the USA, or one-third of the U.S. 
population, and it is the prime reason of disability. While many treatments are 
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1.2.2. Global market of NSAIDs 
Up-to-date treatments for pain principally include non-steroidal anti-inflammatory drugs 
("NSAIDs") for mild to moderate pain and opioids for moderate to severe and chronic 
pain. The opioids are disreputable related to tolerance and dependence, whereas safety 
issues with Cox-2 inhibitors, a significant class of NSAIDs, have limited their use. In 2014, 
the global pain management market for pharmaceuticals and medical devices was worth 
$36.6 billion21 and for NSAID drugs segment was $11.4 billion in 201422. An aging world 
population has prompted the growth in this sector, in addition to an increased incidence 
of obesity and osteoarthritis, as well as changing views towards pain management. Aged 
people are more susceptible to illness such as arthritis, joint or bone pain, epilepsy, 
depression, nerve damage, diabetic neuropathy, and different types of injuries due to low 
resistance levels. The global population of geriatrics (people aged 65 years or more) is 
expected to rise to 2 billion by 2050, accounting for nearly 22% of the projected global 
population. This demographic will lead to a substantial increase in the overall world 
demand for different pain management medications, thereby driving the global pain 
management therapeutics market23. Allied Market Research has estimated that the anti-
inflammatory therapeutics market will reach $106.1bn, globally in 2020. In regard to 
product types, the global pain management drugs market is presently dominated by 
opioids and non-steroidal anti-inflammatory drugs (NSAIDs), whose total share was over 
52% of the market's overall revenues in 2015. North America led the market, accounting 




1.2.3. Opioids market size and abuse  
Opioids are used as anesthetics, cough suppressants, diarrhea suppressants and to 
reduce surgical pain, injury or trauma, cancer pain, as well as pain intensifying from other 
diseases. Opioids are primly used in cancer pain management and end-stage diseases 
in which supportive care is required. The worldwide opioids market was approximately 
US$ 339.24 billion in 2014. 
 By product, the morphine and codeine sections together accounted for around 62% of 
the overall market in 2014. North America was the top market for opioids, and it had 
approximately 65% of the revenue share in 2014, followed by Europe with around a 20% 
share in 2014. Some factors such as increasing palliative care facilities, reformed 
regulations for prescription of opioids, and increased attention of generic manufacturers 
towards Abuse-Deterrent Formulation (ADF) have   driven   the growth of the opioid 
market in North America and Europe. By 2021, the global opioids market revenue is 
postulated to be about US$ 421.6 billion.  
 Prescription opioid pain relievers are usually safe if used for a short time, but because 
they create elation in addition to pain relief, people abuse these (taken in a different way 
or a larger quantity than prescribed, or taken without a doctor's prescription). Logical use 
even as prescribed by a doctor can lead to dependence and, once misused, opioid pain 
relievers can lead to overdose incidents and deaths. 
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More than 90 people in the United States die in a day because of opioids overdose.25 The 
misuse of and addiction to opioids together with prescription pain relievers, heroin, and 
synthetic opioids such as fentanyl is an acute national crisis that influences public health 
as well as social and economic welfare. The Centers for Disease Control and Prevention 
estimates that the total "economic burden" of prescription opioid abuse only in the United 
States is $78.5 billion a year, including the cost of healthcare, lost productivity, addiction 
treatment, and involvement of the criminal justice.26 
In 2015, more than 33,000 persons in the united states died in the aftermath of an opioid 
overdose, including prescription opioids, heroin, and illicitly manufactured fentanyl, a 
powerful synthetic opioid.25 Approximately 2 million people in the United States agonized 
from substance use disorders related to prescription opioid pain relievers, and 591,000 
suffered from a heroin use disorder (not mutually exclusive) in 2015.27 For more 
information about the opioid crisis: 
 About 21 to 29 percent of chronic pain patients misuse prescribed opioids.28 
 Among 8 and 12 percent build up an opioid use disorder.29-31  
 4 to 6 percent who misuse prescription opioids switch to heroin.29-31 





Figure 4 - National Overdose Deaths—Number of Deaths from All Drugs. 
 




Figure 6- National Overdose Deaths—Number of Deaths from Prescription Opioid 
Pain Relievers (excluding non-methadone synthetics).  
 




Figure 8- National Overdose Deaths—Number of Deaths from Benzodiazepines, 
with and without opioids. 
 
1.3 Background  
 
In 1986, Boyle32 and her co-worker synthesized BRL-37959 (5) and found that the 
compound was active as a Non-Steroidal Anti- Inflammatory Drug (NSAID). Zomepirac 
(brand name Zomax), an equipotent drug as BRL-37959, was used as a reference 
compound(Table-1). Zomax replaced morphine for relieving postoperative pain. It is not 
addictive but was withdrawn from the market in 1983 because it caused anaphylaxis, a 










Figure 9-Structural analysis of BRL 37959  
 
                                                                                 
 
Since 1983, no reasonable non-opiate drug is available for postoperative pain. BRL 
37959 may be used as an alternative NSAID, like VIOXX (Rofecoxib), which causes little 
gastric irritation, but has been withdrawn from the market because it increases the risk of 
heart attack. 
 
Table-2: Biological data of racemic BRL-37959 vs Zomax.  
 

















Note: ED50 = Effective dose in mg/kg with 95% confidence limits in parentheses. 







1.4 Aim of the Project:  
 
 Non-selective commercially available COX inhibitors enhance the risk of gastric and or 
duodenal mucosal injury or erosions, ulcers and ulcer problems including bleeding as well 
as lead to nephrotoxicity.18,19. The COX-2 selective inhibitor Celecoxib (Celebrex) 
increases the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction 
and stroke as well as increased nephrotoxicity.   
 
It is well known that COX1 enzyme releases thromboxane that aggregate platelets and 
COX2 enzyme synthesize prostaglandins that act as a vasodilator. This prostaglandin 
keeps blood vessel free from clogging. There is a dynamic balance between the platelet 
aggregation and vasodilation. Therefore, COX inhibitors are active against inflammation, 
pain, and fever as well as different types of cancers.   Considering the enormous potential 
benefits and side effects of non-selective COX inhibitors and selective COX-2 inhibitors, 
our research goal was to find out a COX inhibitor that binds with both COX1 and COX2 
in such a ratio that it would be a safer drug. Also, another aim was to develop a synthesis 
method of the target inhibitor that would be simple, cost efficient and ensure a high yield. 
 
Boyle and her colleges found that BRL-37959 had less gastric irritancy than zomepirac.  
But this drug is not available on the market, in search of its reason we have found that 
the overall yield of Boyle's method is a meager (≤ 5%). 
Benzofuran is an essential building block of BRL 37959. In Dr. Hossain's lab, Matt 
Dudley33 had developed a novel, unprecedented, one pot procedure to synthesize various 
benzofuran derivatives. We have followed this efficient, more economical, large scale 
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potential, selective, high yield and simple process to synthesize benzofuran and designed 
a synthetic route to synthesize BRL-37959 with higher yield. 
 
1.5. Binding mode of NSAIDs with Cyclooxygenase (COX) enzymes 
 
1.5.1. Cyclooxygenase (COX) enzymes and their function  
Phospholipase(PLAs) of plasma membranes release arachidonic acid and 
cyclooxygenase enzymes convert this into prostaglandins. Prostaglandins are signaling 
molecules that facilitate a different group of physiological actions throughout the body. 
Various types of tissues specific prostaglandins such as PGD2, PGE2, PGI2, PGF2, TxA2 
are formed. Prostanoids then exert their effects by signaling through separate G-protein 
coupled receptors (GPCRs).34-35 Prostaglandin signaling is involved in a variety of 
biological functions. For example, prostanoids play a significant role in the maintenance 
of vascular homeostasis. Vascular endothelium-derived PGI2, a vasodilator, and an anti-
thrombotic agent are thought to counterbalance the effects of TXA2, which induces 
vasoconstriction and thrombosis.36-39 PGE2 and PGI2 are also important regulators of 
kidney function and gastric cytoprotection.41-42Pathophysiological responses mediated by 
prostanoid signaling include pain, fever, inflammation, and tumorigenesis37,43,45 and has 
been in reference in.45-47 Phospholipase (PLAs) of plasma membranes releases 
arachidonic acid, and cyclooxygenase enzymes convert it into prostaglandin PGF and 
thromboxane A2 (TXA2), together termed as prostanoids. There are four principal 
bioactive PGs generated in vivo: prostaglandin E2 (PGE2), prostacyclin (PGI2), 





Prostaglandin E2 (PGE2) is generated in large amounts in the body and has a broad 
range of biological functions such as regulation of immune responses, blood pressure, 
gastrointestinal integrity, and fertility. PGE2 plays an important role in causing 
inflammation, redness and pain. PGE2 contributes to the growth of arterial dilation and 
enhanced microvascular permeability that increases blood flow to the inflamed tissue, as 
well as leads to the common sign of inflammation: redness, swelling, and pain.  Pain is 
the result of the action of PGE2 on peripheral sensory neurons and on central sites within 
the spinal cord and the brain.48 
PGI2 and Inflammation  
 
PGI2 regulates cardiovascular homeostasis. PGI2 is found in vascular cells, including 
endothelial cells, VSMCs, and endothelial progenitor cells49-50 PGI2 is produced by the 
consecutive action of COX and PGIS, a member of the cytochrome P450 superfamily that 
positively transforms PGH2 to PGI2. PGIS localizes with COX in the endoplasmic 
reticulum, plasma membrane, and nuclear membrane.41-52 PGIS is initially expressed in 
endothelial cells, where it combines with COX-1,25 although the COX-2-dependent PGI2 
generation by endothelial cells has been stated to be modified in vivo. This is done to   
thrombin, shear stress, oxidized low-density lipoprotein, hypoxia, and inflammatory 
cytokines, as well as upregulation of COX-253-54 which harmonizes it. PGI2 is an effective 
vasodilator and an inhibitor of platelet aggregation, leukocyte adhesion, and VSMC 
proliferatio.47 PGI2 is also antimitogenic and inhibits DNA synthesis in the VSMC.55 These 
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actions of PGI2 are facilitated through specific IP receptors (Table). This receptor is 
expressed in the kidney, liver, lung, platelets, heart, and aorta.56  
Besides its cardiovascular effects, PGI2 is a vital mediator of the edema and pain that 
accompany acute inflammation. PGI2 quickly forms following tissue injury or 
inflammation, and it is present at high concentrations in inflammatory milieus57 PGI2 is 
the most abundant prostanoid in synovial fluid in human arthritic knee joints, as well as in 
peritoneal cavity fluid from mice injected with irritants.58-59  
 
PGD2 and Inflammation 
  
PGD2 is produced in both the central nervous system and peripheral tissues and appears 
to function in both an inflammatory and homeostatic capacity.60 In the brain, PGD2 
regulates sleep and other central nervous system activities, including pain perception. 51-
62 In peripheral tissues, PGD2 is synthesized mainly by mast cells but also by other 
leukocytes, such as DCs and Th2 cells.63-64Two genetically distinctive PGD2-producing 
enzymes have been recognized, including hematopoietic- and lipocalin-type PGD 
synthases (H-PGDS and L-PGDS, respectively). H-PGDS is usually confined to the 
cytosol of immune and inflammatory cells, while L-PGDS is more reserved to tissue-
based expression.64-65 
 
PGF2α and Inflammation 
 
PGF2, originated mostly from COX-1 in the female reproductive system, plays a 
significant role in ovulation, luteolysis, contraction of the uterine smooth muscle, and 
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initiation of parturition.66-67 Recent studies have revealed that PGF2 also plays a major 
role in renal function68, contraction of arteries69, myocardial dysfunction,70-71brain injury,72 
and pain.73Administration of PGF2 produces acute inflammation, and NSAIDs inhibit 
PGF2 biosynthesis both in vitro and in vivo.74 Elevated biosynthesis of PGF2 has been 
found in patients suffering from RA, psoriatic arthritis, reactive arthritis, and osteoarthritis. 
Cardiovascular risk factors, such as diabetes, obesity, smoking, and thickening of the 
intima-media ratio in the carotid artery, have been randomly related with elevations in 
PGF2 metabolites, together with IL-6 and acute phase proteins in body fluids.76—77 The 
sprouting role of PGF2α in acute and chronic inflammation opens up opportunities for the 
design of new anti-inflammatory drugs. 
  
Thromboxane and Inflammation 
 
Thromboxane A2 (TXA2) is a type of thromboxane, synthesized from PGH2 via 
thromboxane synthase, and it is non-enzymatically degraded into biologically inactive 
TXB2. TXA2 is principally derived from platelet COX-1, but it can also be made by other 
cell types, including macrophage COX-2.78-79 TXA2 activity is mainly mediated through 
the TP, which couples with GQ, G12/13, and multiple small G proteins, which in turn 
control several effectors, including phospholipase C, small G protein Rho, and adenylyl 
cyclase (Table-3).92 TP and TP,2 spliced isoforms of TP in humans, communicate with 
different G proteins and undergo hetero-dimerization, which results in alteration to 



























in mice. TP activation arbitrates several physiological and pathophysiological responses, 
with platelet adhesion and aggregation, smooth muscle contraction and pro-function is 
controlled by several factors, such as oligomerization, desensitization, internalization, 
glycosylation, and crosstalk with receptor tyrosine kinases94 TP and TP, spliced iso-forms 
of TP in humans, communicate with different G proteins and undergo hetero-dimerization, 
which results in alteration to intracellular traffic and receptor protein conformations. While 
TXA2 is the favored physiological ligand of the TP receptor, PGH2, in specific, can also 
activate this receptor94.The cutting of TP decreases vascular proliferation and platelet 
activation in response to vascular injury, which delays atherogenesis, and prevents 
angiotensin II– and L-NAME induced hypertension and the associated cardiac 
hypertrophy.95-96 
 
1.5.2. COX reaction 
 
The transformation of AA to the parental prostaglandin, PGH2, takes place at two 
specifically unique but functionally coupled active sites within the COX enzymes.  
The bis-deoxygenation of AA occurs in the L-shaped cavity of the COX active site, leading 
to the formation of the hydroperoxy endoperoxide, prostaglandin G2 (PGG2).85PGG2 
then moves out of the COX site to the peroxidase (POX) active site, where it rapidly is 
reduced by accepting two-electrons to form the hydroxy endoperoxide, PGH243. 
Hydroperoxides except PGG2 can be reduced in the POX active site, and 
commencement of the COX reaction is dependent upon a two-electron oxidation of the 
heme moiety at the POX site. The requirement for heme oxidation at the POX active site 
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to initiate COX catalysis is best described by a branched-chain mechanism, as shown in 
Figure 11. The two-electron oxidation of heme takes place in conjunction with the two-
electron reduction of a hydroperoxide substrate, and results in the formation of a ferryl-
oxo protoporphyrin radical cation ((PPIX•) +Fe4+O) designated Compound I.86-87 In the 
presence of a reducing co-substrate, two subsequent one-electron reductions restore the 
heme moiety to its original state.88-89Otherwise, Compound I can abstract a hydrogen 
from Tyr-385 in the COX active site, which results in the formation of a tyrosyl radical, 
thus commencing the oxygenase reaction. 
 
1.5.3. Structure of COX enzymes 
1.5.3.1.  General COX structure  
In 1994, the first three-dimensional structure of COX-1 was made, and two years later the 
crystal structure of COX-2 was obtained.89,90 Subsequent cleavage of the signal 
sequence, mature COX-1 contains amino acid residues 25-600, with residues 33-586 
displaying clear electron density in crystallographic analysis89. Also, residues 33-583 
were determined in the first crystal structure of COX-2; 35 amino acids at the C-terminus 
could not be traced.90 A 14-amino acid elimination at the N-terminus of COX-2 results in 
the numbers of most COX-2 amino acids to be 14 units lower than those of COX-1, but 
by convention, the amino acids of both isoforms are referred to by the numbering of the 




Figure 11- Branched chain mechanism for COX catalysis. In the POX, active site, the 
heme moiety, (PPIX)Fe3+, undergoes a two-electron oxidation to form Compound 
I, (PPIX•) Fe4+O, whereas the hydroperoxide substrate (ROOH) undergoes a two-
electron reduction. The enzyme can return to its original state by two subsequent 
one- electron reductions or the radical can be transferred to a tyrosine residue in 
the COX active site. While AA is bound within the COX active site, the newly formed 
tyrosyl radical can abstract the 13-pro-(S) hydrogen from the fatty acid substrate. 
AA undergoes several radical rearrangements in addition to two oxygenation 
reactions to provide the development of the hydroperoxy endoperoxide, PGG2. 
The radical is then shifted back to the tyrosine residue to allow the initiation of 






discloses that the two isoforms have virtually superimposable structures with each. COX 
monomer consists of three domains:  an epidermal growth factor (EGF)-like domain, a 
membrane binding domain, and a large globular catalytic domain, which holds the 
cyclooxygenase (COX) and peroxidase (POX) active sites.89-91 The COX enzymes are 
found as homodimers with an extensive dimer interface created by the EGF-like and 
catalytic domains.92 
Table 3: Summary of the structure, distribution and regulation of COX-1 and COX-2  
 
 COX1 COX2 
cDNA   Chromosome 9; 22kB Chromosome 1; 8.3kB  
mRNA 2.8kB 4.5kB 
Protein 72kDa;599 amino acids 72kDa;604 amino acids 
 Amino acids: 90% between species for both isoforms; similar 
Vmax and Km values for arachidonic acid 
Differences Glucocorticoids inhibit expression of COX-2, not COX-1; the active 
site of COX-2 is larger than that of COX-1 
Regulation Predominantly constitutive. 
Increased 2- to 4-fold by 
inﬂammatory stimuli  
Predominantly inducible 
(10- to 20-fold) 




Most tissues, but particularly 
platelets, stomach, kidney 
Induced by inﬂammatory 
stimuli and mitogens in 
macrophages/ monocytes, 
synoviocyes, chondrocytes, 
ﬁbroblasts, endothelial cells. 
Induced by hormones in the 
ovaries and foetal membranes. 
Constitutive expression in the 





Domain construction   
COX, a monotopic membrane protein that binds with phospholipid bilayer of the plasma 
membrane as if it was a basic membrane protein.  
 
The membrane-binding domain (residues 73-116) consists of four short amphipathic α-
helices (A-D). The helices are placed approximately orthogonal to one another forming a 
hydrophobic surface model for introduction into a single face of the membrane bilayer. 
The helices of the membrane binding domain are also surrounded by a somewhat large 
open area that has been termed the "lobby," as it is assumed that substrates and 
inhibitors must travel through this zone to enter the active site located within the catalytic 
domain. 
The catalytic domain is physically homologous to mammalian myeloperoxidase, 
indicating that the COX enzymes evolved from soluble heme-dependent peroxidases93. 
This main domain of the COX monomer largely consists of a α-helical secondary 
structure. The POX active site is located in a solvent-accessible trench at the top of the 
catalytic domain while the COX active site lies at the vertex of a large, L- shaped 
hydrophobic channel that ranges from the membrane-binding domain into the catalytic 
domain. Inside the COX channel, the catalytic and membrane binding domains are 









The EGF-like domain is composed of a short sequence of amino acids at the N- terminus 
(residues 34-72) of the protein, and its particular function remains unknown. However, it 
has recommended that this domain may start and retain interactions necessary for the 
insertion of COX into the membrane bilayer93. 
POX active site:  
The peroxidase active site (shown in Fig-12) is the position of heme binding where 
His-388 serves as the proximal heme ligand. Gln-203 and His-207 are located on 
the distal side of the heme, approximately 5 Å from the heme iron, but do not 
coordinate the metal88. It is assumed that these residues play a key role in the two- 
electron reduction of the hydroperoxide substrate.45 Mutation of His-388, Gln-
203, or His-207 results in a dramatic reduction in peroxidase activity.44,94 Recent 
studies confirm that, while the kcat/Km for peroxidase activity of G203V oCOX-1 
is 17% that of WT enzyme, the mutant enzyme holds full COX activity and has a 
specific activity corresponding to that of WT proposing that this Glu-203 is not 
needed for the initiation of COX catalysis.95 
In contrary to the majority of peroxidases, the POX active site of COX enzymes is 
exposed to solvent and can, therefore, hold large alkyl peroxide substrates. The 
opening of the POX active site also permits for relatively easy dissociation of small 
ligands, including heme, in and out of the active site cavity. Due to the nature of 
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POX active site and the reactivity of the heme moiety, crystallization of substrates 
or products attached to the peroxidase active site has been difficult. Lately, the 
2.0 Å crystal structure of oCOX-1 in complex with an analog of the non-steroidal 
anti- inflammatory drug (NSAID) flurbiprofen presented the first view of a ligand 
bound to the POX active site (PDB ID: 1Q4G).96 A detailed explanation of NSAIDs 
as COX inhibitors is provided below. Though, in this specific structure, a glycerol 
molecule, used as a cryoprotectant, lies between Gln-203 and His-207 with the 1-
hydroxyl group located roughly above the heme iron (Figure 12)96. The 3-hydroxyl 
group forms hydrogen bonding interactions with a water molecule coordinated to    
His-20794. The position of this glycerol molecule is likely to mimic the binding 
conformation of the peroxide moiety of alkyl hydroperoxide substrates. This 
structure was used as the basis for docking and molecular dynamics studies for 
predicting the productive binding mode of the hydroperoxy endoperoxide 









Figure 12- Glycerol molecule bound within the POX active site of COX-1. Heme (red stick 
structure) is shown bound in the POX active site in addition to a glycerol molecule (blue and red) 
shown in ball-and-stick mode. Key residues for peroxidase activity are shown in turquoise. The 
catalytic tyrosine is shown in orange. PDB ID: 1Q4G.  
 
1.6 COX active site 
The COX active site channel ranges 25 Å from the membrane binding domain to the 
interior of the catalytic domain; the catalytic center is placed on the upper half of the 
channel from Arg-120 to Tyr-385. Although the COX-1 and COX-2 active sites are 
somewhat similar, the COX-2 active site is about 20-30% larger than that of COX-1(Figure 
13). The size variation is rather assigned to a single amino acid change (Ile-523 in COX-
1, Val in COX-2) that limits the gateway to a pocket of the main active site channel 99. 
Substitution of secondary shell residues, Ile-434 and His-513, in COX-1 for Val-434 and 










Figure 13- Solvent accessible surfaces in the cyclooxygenase active site of COX-1 and COX-2. The 
catalytic domains of the COX proteins are shown as red in a ribbon diagram with the membrane binding 
domains (predominantly helix D) shown in green. Residues lining the COX active site of both proteins are 
shown in white with the solvent accessible surfaces in the active site designated as translucent light-blue. 
 
It is confirmed from Crystal structures and molecular models of ovine COX-1 (oCOX-1) 
and murine COX-2 (mCOX-2) that the carboxylic acid of the arachidonic acid ion-pairs to 
the guanidinium group of Arg-120 and hydrogen bonds to Tyr-355. The aliphatic 
backbone stirs up into the top of the cyclooxygenase active site from the hydrophobic 
channel and then forms a distinct bend in the proximity to Tyr385 (Figure 14).100-104 In 
these structures, because of van der Waals interactions, all most all the of contacts are 




                           
                             Figure 14- Arachidonic acid bound in the active site of oCOX-1.32  
                                 The carboxylate of the substrate ion-pairs with Arg-120 and hydrogen 
                                 -bonds with Tyr-355 at the construction site, projects up the hydrophobic  
                                  channel, and makes an L-shaped   bend around Tyr-385. The heme  
                                  prosthetic group is designated in red. Residues that are in contact with  
                                  arachidonic acid in the active site channel are shown in yellow. 
 
of arachidonic acid links, up in a narrow channel at the top of the active site and is 
surrounded by six aromatic amino acids. Mutation of Gly-533 at the top of this channel 
caps off the channel and ends the oxygenation of arachidonic acid but not that of fatty 






1.7 Binding mode of NSAIDs to COX enzymes 
 
1.7.1 Aspirin  
 
Aspirin covalently alters both COX-1 and COX-2 over acetylation of Ser-530, it is 10-100 
times more potent against COX-1 than against COX-2.105-107The cause for this variance 
in inhibitor potency against the two cyclooxygenase isoforms is ambiguous. Without 
acetylation, both COX enzymes predominantly create PGG2 and small amounts of 
lipoxygenase-type products (hydroperoxy fatty acids), with either R or S stereochemistry 
for the peroxide group at C-15.107-108 Acetylation of Ser-530 entirely stops arachidonate 
catalysis and product formation in COX-1 but permits the synthesis of 15(R)-
hydroxyeicosatetranoic acid and 11(R)-hydroxyeicosatetranoic acid in COX-2. 103-104  This 
disparity inhibition of the COX enzymes by aspirin is due  to  the  larger volume of the 
COX-2 active site produced by the Val-523 substitution at the mouth of the side pocket 
109.Mutation of Val-523, Arg-513, and Val-434 in COX-2 to their COX-1 equivalents (Ile-
523, His513, Ile-434) consequences in the inhibition of 15- and 11(R)-
hydroxyeicosatetranoic acid formation subsequent treatment with aspirin.110 
The crystal structure of COX-1 bound with 2-bromoacetoxybenzoic acid (an aspirin 
analog) shows the integration of the bromoacetyl group at Ser-530 (Figure 15).111 Two 
rotamers of the bromoacetyl group exist that blockade the active site channel to different 
degrees; this may assist to clarify the different results of acetylation of COX-1 and COX-





                         Figure 15- Crystal structure of an aspirin analogue in the active site of 
                     oCOX-1.57 The bromoacetyl group of the aspirin analogue 2-bromoacetoxy-  
                     benzoic acid is shown covalently bound to Ser-530 in the COX active site  
                    (red and orange linker). The product of the reaction, salicylic acid, is shown  
                     in the active site with its carboxylate making hydrogen bonds with Arg-120 
                     and Tyr-355 at the construction site. The bromoacetyl group of the inhibitor    
                     and the salicylic acid product are shown in green and are colored by atom. 
                    Key active site residues are shown in yellow. 
 
selective delivery of the acetyl group to Ser-530. The salicylate carboxyl group ion-pairs 
to Arg-120, which is positioned immediately below Ser-530. Mutation of Arg-120 to Gln or 
Ala removes ion-pairing and hydrogen bonding interactions with the salicylate group and 
significantly reduces aspirin acetylation of Ser-530.112 Another aspirin analog, o-
acetylsalicylhydroxamic acid113 also binds in the COX-1 active site channel, acetylates 
Ser-530, and hydrogen-bonds with Arg-120 at the construction site. The acetyl group on 
Ser-530 propels into the active site instantly below Tyr-385, shut down the top of the 
channel and blocking the entrance of substrate to the catalytic tyrosyl radical. In the 
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crystal structures of COX with aspirin analogs, a hydrogen bond is present between the 
carbonyl oxygen of the acetyl adduct and the phenolic hydrogen of Tyr385.112,113 The 
presence of Tyr-385 across the active site from Ser-530 plays a significant role of 
acetylation.114 Mutation of Tyr-385 to Phe decreases aspirin acetylation of the serine 
hydroxyl by 93%.112 The hydrogen-bonds between Tyr-385 and the acetyl group of 
aspirin, which increases its reactivity by stabilizing the negative charge of the tetrahedral 
intermediate of acetylation. This action of Tyr-385 is like the stimulation of substrate 
acylation of serine proteases through the oxyanion hole in the active site.115Remarkably, 
aspirin acetylates heme-reconstituted enzyme 100-fold more rapidly than 
apoenzyme.116One probable clarification for this consequence is that the heme group 
restricts protein conformational mobility and easiness enzyme-aspirin interactions. The 
inhibition of COX enzymes by aspirin is also based on the oxidative state of the enzymes; 
activation of COX with peroxides to form the Tyr-385 tyrosyl radical reduces acetylation 
by aspirin.117The necessity of Tyr-385 and the heme prosthetic group for acetylation of 
Ser-530 underlines the dynamic roles of the different parts of the cyclooxygenase active 
site in the overall inhibition of its enzymatic activity by aspirin. 
1.7.2.  Flurbiprofen and Ibuprofen  
X-ray crystallography of COX-inhibitor complexes and site focused mutagenesis studies 
have assisted revealing the molecular basis for the time-dependent inhibition of some aryl 
propionic and aryl acetic acid inhibitors. COX-1 crystal structures of competitive reversible 
(ibuprofen and methyl flurbiprofen) and time-dependent (flurbiprofen and alclofenac (2-
(4-(allyloxy)-3-chlorophenyl) ethanoic acid)) inhibitors disclose the same binding 
conformation of inhibitor in the active site. It indicates that the mechanism of time-
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dependent inhibition of COX thru NSAIDs does not include broad conformational changes 
in the enzyme structure or the binding of the inhibitor to diverse, active sites. In the crystal 
structure of COX-1 with flurbiprofen, the inhibitor binds to the cyclooxygenase active site 
with the carboxylate of the inhibitor. Then it makes hydrogen-bond that links with Arg-120 
and Tyr-355 at the constriction site (Figure 16A)118, The structurally alike, but kinetically 
different, ibuprofen binds in an almost same style in the COX-1 active site, creating an 
ion pair with Arg-120 and a hydrogen bond with Tyr-355 (Figure 17B).118These 
crystallographic results recommend that the kinetic dissimilarities between competitive, 
reversible and time-dependent, functionally irreversible inhibitors cannot entirely clarify 




Figure 16- Flurbiprofen and ibuprofen bound in the active site of ovine COX-1. Panel A shows a time-
dependent and functionally irreversible inhibitor, flurbiprofen (green), in the oCOX-1 active site with its 
carboxylate coordinated to Arg-120 and Tyr-355 at the constriction site. Panel B shows a competitive 







Crystal structure of indomethacin and COX-2 demonstrates that indomethacin binds 
intensely within the cyclooxygenase active site (Figure 17A).119 The p-chlorobenzoyl 
group progresses up into the active site channel, and the chlorine atom interacts with 
Leu-384 at the top of the active site, whereas the benzoyl oxygen interacts with Ser-530. 
The benzoyl group itself is stabilized by hydrophobic interactions with Leu-384, Tyr-385, 
Phe-381, and Trp387. The carboxylate of indomethacin creates a salt bridge with Arg-
120 and builds additional interactions with Tyr-355 at the constriction site. The o-methoxy 
group makes a large cavity provided by Ser-353, Tyr-355, and Val-523. The indole ring 
interacts with Val-349, and the 2′-methyl group impels into a small hydrophobic pocket 
formed by Val-349, Ala-527, Ser-530, and Leu-531 (Figure 17B).119 Mutagenesis of Val-  
 
       Figure 17 - Crystal structure of indomethacin in the active site of murine COX-2.60 Panel A     
       shows key active site residues important for inhibitor binding. Indomethacin is shown in     
       green and is colored by atom. Arg-120, Tyr-355, and Glu-524 at the constriction site are   
       shown in purple. Residues that constitute the small hydrophobic binding pocket (Val-349,   
       Leu-531, Ala-527, and Ser-530), as well as additional active site residues (Tyr-385), are     
       shown in yellow. Panel B is a space-filling model of the 2α-methyl group of indomethacin  




349 to alanine or leucine shows that introduction of the 2′-methyl group of indomethacin 
into this small pocket is a crucial interaction responsible for the time-dependent inhibition 
of COX enzymes by this inhibitor.120 A V349 A mutant enlarges the pocket size and raises   
the potency of indomethacin compared to wild type mCOX-2 (0.08 vs. 0.25 µM), while a 
V349L mutant cuts the pocket size and decreases the potency of the inhibitor (4.0 µM). 
The KI of V349A for indomethacin association is almost 4-fold lower than wild-type 
mCOX-2 with a slight increase in k2 (0.074 vs. 0.052 s-1), while V349L shows a 3-fold 
increase in KI that accompanies a k2 of 0.074 s-1. Indomethacin reveals slow, time-
dependent, and functionally irreversible inhibition of both wild-type mCOX-2 and the 
V349A mutant with no significant reverse rate constant (k-2) for the second inhibitory step 
(eq 2). However, indomethacin exhibits reversible inhibition with the V349L mutant with a 
measurable k-2 of 0.01 s-1. A2 ′-des-methyl analogue of indomethacin is a poor inhibitor 
of mCOX-2 and the V349 mutants and is quickly competed off the enzymes by 
arachidonic acid. 2-Des-methyl indomethacin does not inhibit COX-1 at all. Hence, a 
critical factor of the time-dependent inhibition of COX by indomethacin is endorsed to the 




Diclofenac inhibition of COX-2 is not affected by mutation of Arg-120 to alanine or of Tyr-
355 to phenylalanine, with IC50 values for inhibition that is comparable to that of wild-type 
mCOX-2 (wt, 77 nM; R120A, 257 nM; Y355F, 137 nM).60 However, a S530A COX-2 
mutant is resistant to diclofenac inhibition (IC50 > 50 µM), proposing that Ser-530 is 
important for inhibitor binding in the COX-2 active site. In support of this hypothesis, a 
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S530M COX-2 mutant shows a greater than 240-fold growth in IC50 for diclofenac over 
wild-type enzyme121.Also, diclofenac quenches the internal protein fluorescence of apo 
COX-1 but does not quench the fluorescence of the aspirin-acetylated enzyme, 
recommending that diclofenac must interact with Ser-530 in the COX active site for 
binding and inhibition81.Most crystal structures of COX enzymes with carboxylic acid-
containing NSAIDs demonstrate the inhibitors located with their carboxylates coordinated 
to Arg-120 and their aromatic functional groups stir up into the cyclooxygenase active 
site. In contrary to diclofenac binds in the active site of COX-2 in a distinctive inverted 
binding mode with its carboxylic acid moiety hydrogen-bonded to Ser-530 and Tyr-385 
(Figure 18).104, 105 The inhibitor also builds great van der Waals interactions with several 
hydrophobic residues inside the active site. For example, the phenyl acetic acid ring is 
enclosed by the side chains of Tyr-385, Trp-387, Leu-384, and Leu-352. The 
dichlorophenyl group makes van der Waals interaction with Val-349, Ala-527, Leu-531 
(the indomethacin binding pocket), and Val-523. Unlike most other NSAIDs with 
carboxylic acid moieties, neither Tyr-355 nor Arg120 creates contact with the inhibitor. 
The unique binding mode of diclofenac is like the structure of the nonproductive complex 
of arachidonic acid. COX-2 in which the substrate binds in an inverted conformation with 
its carboxylate coordinated to Ser-530 and Tyr-385.41This positioning contrasts with most 
structures resolved for fatty acid substrates attached to COX, including arachidonic acid, 
where the carboxylate of the substrate forms hydrogen bonds or ion pairs with Tyr-355 





                     Figure 18- Crystal structure of diclofenac in the active site of murine 
                   COX-2.60 Diclofenac binds in a novel, inverted orientation with its 
                   carboxylate coordinated by Tyr-385 and Ser-530 at the top of the active 
                   site. Diclofenac is shown in green and is colored by atom with each 
                   chlorine atom colored in light-green. Arg-120, Tyr-355, and Glu-524 
                   at the construction site are shown in purple. Additional key active site 
                   residues are shown in yellow.104 
 
conformation of arachidonic acid in COX-2 highlight the significance of Ser-530 and Tyr-
385 in ligand association and the chelation of negative charges in COX-2 and may 
characterize a new binding mode demonstrated by some classes of NSAIDs. 
1.7.5. Celecoxib analogue 
 
The first crystal structure of human COX-2 (hCOX-2) displays that there is an overall 
variance in the size and shape of the COX-2 active site compared to that of COX-130. 
Almost 25% larger active site of COX-2 is due to the single Val-523 substitution (Ile in 
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COX-1) in the active site and by the Arg-513 and Val-434 substitutions (His-513 and Ile-
434 in COX-1) in the secondary shell. The crystal structure of mouse COX-2 with the 
celecoxib analog 4-(5-(4-bromophenyl)-3(trifluoromethyl)-1H-pyrazol-1-yl) benzene- 
sulfonamide (SC558) discloses that the sulfonamide group of the inhibitor binds in the 
side pocket adjacent to Val-523 in COX-2 (Figure 19).31 Access to this pocket is 
constrained in COX-1 because of the extra steric bulk of Ile at this location. The binding 
of the sulfonamide group of SC558 in this side pocket is expedited by the additional 
substitutions of Val-434 and Arg-513.31 The sulfonamide group of SC558 interacts with 
His-90, Gln-192, and Arg-513. The Arg-513 is preserved in all COX-2 enzymes and 
provides a positive charge in the side pocket. SC558 forms hydrogen bonds between its 
sulfonyl oxygens and His-90 and Arg-513, and the sulfonamide nitrogen hydrogen-bonds 
to the backbone carbonyl oxygen of Phe-518. The bromophenyl ring of 4 binds in a 
hydrophobic cavity formed by Ser-530, Leu-359, Trp-387, Tyr-385, Leu-384, and Phe-
381, and the trifluoromethyl group of the pyrazole ring binds in a small pocket provided 
by Met113, Val-116, Val-349, Tyr-355, Leu-359, and Leu-531. Confirming the prior 
mutagenesis studies on human COX-2, the crystal structure of mouse COX-2 and 
compound 4 exhibits that the selective, time-dependent step in diaryl heterocycle 
inhibition of COX-2 is probably the placing of the methyl sulfonyl or sulfonamide group of 
the inhibitor past Val523 in COX-2 and into the side pocket. Val523 is replaced in COX-1 






            Figure 19- Crystal structure of the celecoxib analogue, SC558, in the active site  
          of murine COX-2.31Compound SC558 is shown in green and is colored by atom. The key  
          active site residues important   inhibitor binding is highlighted. Arg-120, Tyr-355, and  
          Glu-524 at the constriction site are shown in purple. Residues that constitute the small 
          hydrophobic binding pocket (Val-349, Leu-531, Ala-527, and Ser-530) and the COX-2  
          side pocket (Val-523, Arg-513, and Gln-192) are shown in yellow. Tyr-385 and Val-434  
          are also designated in yellow. 
 
1.7.6. Naproxen and its analogs  
Naproxen, a NSAIDs widely used for analgesic, anti-pyretic, and anti-inflammatory activity 
(Fig. 20). It has been stated that it is active in the prevention of bladder cancer growth 
even when administered several weeks after the tumor-initiating agent.126 Naproxen, is 
non-selective COX inhibitor that binds both COX-1 and COX-2 and have gastrointestinal 
side effects. In recent growing evidence suggests that it has no cardio vascular side 
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effects when administered in the higher doses that deliver continued inhibition of platelet 
COX-1 during the dosing interval (e.g.500 mg twice daily).127-129 
 
Naproxen inhibited oCOX-1 with an IC50 value of 340 nM and mCOX-2 with an IC50 value 
of 180 nM and showed greater than 80% inhibition in the presence of 500 nM AA (Fig. 
21). Binding of Naproxen with COX — Aryl carboxylic acid inhibitors bind in one of two 
orientations in the COX active site (Fig.20).130 Flurbiprofen attach canonically with its 
carboxylate moiety ion-paired and hydrogen-bonded to the constriction site residues Arg-
120 and Tyr-355 (Fig. 20B).131-138 In contrast, diclofenac binds in a reversed orientation 
in which its carboxylate is hydrogen-bonded to the side chains of Tyr-385 and Ser-530 





FIGURE 20. Chemical structures of NSAIDs and crystal structures of flurbiprofen and diclofenac bound in mCOX-2 
active site. A, chemical structures of naproxen, flurbiprofen, diclofenac, and indomethacin. The structures of flurbiprofen 
(Protein Data Bank entry 3PGH; inhibitor carbon atoms colored gold) (B) and diclofenac (Protein Data Bank entry 
1PXX) (C) bound at the COX-2 active site show the opposing binding modes that position their acidic groups either 
coordinated to the constriction residues Arg-120 and Tyr-355 at the base of the active site or to the catalytic Tyr-385 
as well as Ser-530 at the top of the pocket.130 
 
Mutation of Tyr-355 to Phe in mCOX-2 ceased inhibition by naproxen (Fig.22A),130 while 
mutation of Arg-120 to Gln slightly amplified the potency of inhibition as displayed by an 
improved IC50 and a greater extent of inhibition (90%).Mutation of Arg-120 to Ala lead to 
a complete loss of enzyme inhibition by naproxen (Fig. 22A). In concert, these outcomes 
suggest that the carboxylate group of naproxen binds at the construction site in the 
canonical orientation, coordinated to Tyr-355 and Arg-120. To thoroughly inspect the 
41 
 
binding mode predicted from this studies Duggan and his co-worker.130 determined the 




 FIGURE 21. Effect of preincubation of enzyme and inhibitor on COX inhibition by naproxen.  
                     Closed circles (F) represent incubations in which (0.05–25 nM) and AA (500 nM) 
                     were added simultaneously to COX. For the incubations represented by open 
                     circles (E), COX was preincubated with naproxen (0.05nM) for 5 min before the 
                     addition of 500 nM AA. A is representative of incubations with oCOX-1, and B  
                     represents reactions withmCOX-2. The reaction with substrate was allowed to  
                     proceed for 8 s before quenching. Substrate consumption was analyzed by TLC  
                     as described. Each data point is the mean of at least two experiments in duplicate. 
                     Error bars, S.E. which eradicate inhibition by flurbiprofen but have no effect on inhibition  
                     by diclofenac.130  
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Figure 23- Crystal structure of naproxen bound to mCOX-2. A, difference electron 
density map (F0Fc) contoured at 3.5α of the COX-2 active site prior to the addition of 






resolution COX structure to date and among the highest resolution membrane. The 
topology of the COX dimer and active site are like those of previous studies. To some 
extent, amazingly, the residues lining the active site were exposed in single 
conformations, even though the fact that many of them were surrounded only by solvent. 
The resolution of this structure allowed the detection of a β-OG molecule lying on the 
external side of the constriction, at the base of the funnel-shaped entrance to the active 
site (lobby region), like to high resolution structures of COX-1(e.g. Protein Data Bank 
entry 2AYL).140 A solvent molecule is frequently observed hydrogen-bonded toTyr-385 
and Ser-530 in the active site; nevertheless, when this density was fitted with a water 
molecule in the current structure, a 5α residual electron density peak kept on at that 
position. When equipped with a chlorine atom, the residual peak gone, and the atom 
polished to a temperature factor like neighboring protein and inhibitor atoms. A peak in 
the great difference map at the same location delivered further indication that the peak 
was a chlorine atom. While the physiological consequence of chloride binds in gat this 
position is unknown, chloride ions have been used earlier to recognize the binding site of 
molecular oxygen in various proteins, including dioxygenases.141-142 This increases the 
probability that the Chloride ion may be revealing of the position of molecular oxygen 
before assimilation into COX substrates. Strong electron density was detected for a single 
orientation of naproxen binding within the COX-2 active site, making no contacts in the 
COX-2 side pocket or lobby region (Fig. 23). As projected by the mutagenesis data, the. 
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Figure 24. Inhibition of WT and W387F mCOX-2 by naproxen and  
naproxen analogs. Following a 20-min preincubation of naproxen  
(A), p-naproxen (B), or a p-methylthio naproxen(C) with mCOX-2(●) 
Or W387F mCOX-2(O), [1-14 C] AA(50µM) was added and allowed 
to react for 30s prior to termination with organic solvent. Concentra- 
tions of inhibitors ranged from 0.25 µM. Product formation was mea- 
sure, by TLC as described. Each data point is the mean of at least  




binding mode of naproxen is alike that of other members of the 2-aryl propionic acid family 
of NSAIDs with the carboxylate group of naproxen participating in hydrogen-bonding 
inter-actions with Arg-120 (2.8 and 2.9 Å) and Tyr-355 (2.5 Å) at the base of the active 
site. The remains of the interactions between the compound and protein were van der 
Waals contacts. The (S)--methyl group of naproxen puts in the hydrophobic cleft adjacent 
to Val-349, whereas the naphthyl backbone of naproxen makes hydrophobic contacts 
with Ala-527, Gly-526, and Leu-352. Remarkably, the side chain of Leu-352 accepts an 
alternate conformation from that observed in the co-crystal structures of flurbiprofen, 
indomethacin, and diclofenac bound to mCOX-2. The p-methoxy group of naproxen is 
focused on the apex of the COX active site and forms van der Waals interactions with 
Trp-387 and Tyr-385. As mentioned above, the mCOX-2 naproxen crystal structure 
shows that the (S)--methyl group of naproxen is oriented in a conformation like that of the 
-methyl group of flurbiprofen and creates hydrophobic contacts with Val-349 as well as 
Leu-359.131 Naproxen inhibited V349A mCOX-2 with a potency and extent of inhibition 
similar to those of WT mCOX-2(IC50 3.5M, 75% inhibition), but the V349I and V349L 
mutants were both more sensitive to inhibition (IC50 0.28 and 0.35 M, greater than 95% 
inhibition. The rise in inhibition detected when naproxen was tested against V349I or 
V349L could result from amplified hydrophobic interactions between the-methyl group 
and residue 349.To trial this hypothesis, 2-des-methyl naproxen was tested against the 
WT and V349I/L mutant enzymes. Elimination of the methyl group led to a substantial 
reduction in inhibition of WT COX and the V349I/L mCOX-2 mutants (maximum inhibition 
of 20% at concentrations up to 25 M) (Table 3a and data not shown). The accumulation 
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of bulk at the-position also caused to a loss of potency because the-ethyl analog of 
naproxen showed no inhibition of either wild-type COX-1 or COX-2 enzymes in our 
standard IC50 assay (Table 1). Likewise, bulkier substitutions at the-position of flurbiprofen 
impart a complete loss of inhibition of COX-131. Hence, the (S)-methyl group is a vital 
determinant of naproxen efficacy, and it cannot be substituted with smaller (hydrogen) or 
larger (ethyl) substituents. The naproxen-COX-2 crystal structure displays that the p-
methoxy group interacts with Trp-387 by van der Waals associates with two carbon atoms 
of the side chain, C2 (3.4 Å) and C 2(3.6 Å), the latter being the position of the side chain 
unique spatially to tryptophans. Trp-387 is positioned at the top of the COX active site 
near the catalytic residue, Tyr-385, and has been exposed to be an important residue for 
the proper locating of AA within the active site to yield the cyclooxygenase product, PGG 
2. The W387F mCOX-2 mutant enzyme procedures relatively little amounts of PGG 2 but 
grown amounts of the uncyclized product, 11-hydroxyeicosatetraenoic acid.144 We 
verified the W387F mutant for sensitivity to naproxen inhibition. A higher protein 
concentration was applied as the mutant’s decreased catalytic activity. Naproxen had a 
negligible inhibitory effect on W387F, displaying only 25% inhibition at 25M (Fig.22B). 
The W387F mutation has not been studied with other inhibitors, so it was examined 
against several other carboxylate-containing NSAIDs. Amazingly, the IC50 values for 
diclofenac, flurbiprofen, and indomethacin against the W387F mutant enzyme were 
similar to earlier reported values against wild-type enzyme (87,120, and 250 n, 




Diclofenac and indomethacin only form a single contact point to the Trp side chain, to the 
C 2 position, one strictly imitated by phenylalanine.144While flurbiprofen also crates 
interactions with both carbon atoms of the Trp residue, they originate from a phenyl ring 
of the inhibitor that is earlier strengthened by other interactions, making the one with the 
Trp possibly less important for binding. In naproxen, the oxygen of the p-methoxy group 
lies within van der Waals contact range only of the Trp side chain. Thus, the interaction 
between Trp-387 and naproxen appears to be unique among carboxylate-containing 
NSAIDs. 
 
To more investigation, the interaction between the methoxy group and Trp-387, two 
naproxen analogs, were synthesized in which an ethyl or methyl thio group was replaced 
for p-methoxy to present variations in size and polarity as well as to eliminate the 
possibility of hydrogen-bonding interactions. The methyl-thio analog has been stated to 
exhibit anti-inflammatory activity in vivo but has not been verified in vitro. The ethyl analog 
has not been testified. Both the p-ethyl and p-methyl thio analogs could inhibit wild-type 
mCOX-2 to the same extent as naproxen (IC50 0.67 and 0.77 M in our standard IC50 
assay) (Table 3a). Remarkably, both analogs displayed a loss of potency compared with 
naproxen when tested against oCOX-1 so that no IC50 value could be determined at 
inhibitor concentrations up to 25 M. (Table 1).  An increase in COX-2 selectivity at reduced 
substrate concentrations (500 nM and 5M AA). More notable yet, both analogs inhibited 
W387F as well as they inhibited wild-type enzyme (Fig. 24). The variance in sensitivity of 
W387F mCOX-2 to naproxen and the p-ethyl and p-methyl thio analogs facilitate to 
crystallize the complex of mCOX-2 with the p-methyl thio naproxen derivative. A structure 
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of this complex was purified at 2.3 Å resolution (Fig.25). Like naproxen, the inhibitor is 




Figure 25 Crystal structure of p-methylthio naproxen bound to mCOX-2. A,stereoview of the(Fo Fc ) 
difference electron map contoured at 3.0ճ prior to the addition of the inhibitor to the model.B,ste-review of 
the p-methylthio naproxen analog bound within the mCOX-2 active site.The carboxylate partici-pates in 
hydrogen-bonding interactions with Arg-120 and Tyr-355 at the base of the active site; this interaction is 




nearest equivalent atoms (distance 0.2 Å) between the two compounds are the sulfur and 
oxygen atoms of the p-methyl thio and p-methoxy groups, respectively. The carboxylate 
tails of the compounds vary greatest in position, with the p-methyl thio-substituted 
compound extending 0.5 Å less deeply into the binding site. The p-methyl thio naproxen 
analog adopts a binding conformation similar to that of naproxen, maintaining many of 
the same interactions with surrounding residues. For instance, the carboxylate makes 
hydrogen-bonding interactions with Arg-120 (2.9 and 3.0 Å) and Tyr-355 (2.5 Å), and 
the(S)--methyl group builds hydrophobic contacts with Val-349 and Leu-359. The 
naphthyl backbone participates in van der Waals interactions with Ala-527 and Gly-526, 
whereas the methyl thio substituent at the 6-position contacts Tyr-385 and Trp-387. In 
contrast to naproxen, the p -methyl thio naproxen analog is not within van der Waals 
distances of Leu-352. This difference arises from the Leu side chain exhibiting different 
side chain conformation in the two structures, with that observed in the methyl thio analog 
being consistent with that seen in the previously published NSAID mCOX-2 co-crystal 
structures (three of four monomers). No explanation for the rotation of the residue in the 
naproxen structure or its failure to rotate in the methyl thio derivative structure is readily 
apparent. Comparison of the two crystal structures also indicates that Val-523 makes 
hydrophobic contacts with the naphthyl backbone of the p-methyl thio naproxen analog 
but does not contact naproxen. This observation results from the relative shift of the 
compounds within the active site. kinetic studies as well as an extensive mutagenesis 
study, exploration of the structure-activity relationship, and x-ray crystallography were 
carried out to find out the molecular determinants of COX inhibition by naproxen. Key 
interactions between the inhibitor and constriction site residues as well as a novel 
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interaction with Trp-387 (Fig. 22) was identified. Substitution of an ethyl or methyl-thio 
group for the p-methoxy substituent created COX-2- favoring naproxen analogs that were 
unchanged by mutation of Trp-387 to Phe (Fig.24). X-ray crystal structures of both 
naproxen and the p-methyl thio analog bound to mCOX-2. The combination of 
mutagenesis, chemical elaboration of naproxen analogs and structural studies clearly de-
fined the contribution of protein and inhibitor atoms to affinity (Figs.23 and 25). 
 
Naproxen is a comparatively simple molecule with only three functional groups dispersed 
on opposite ends of the naphthyl scaffold. Obtained data specify that each of these 
substituents is essential for potent inhibition of both COX isoforms and that very slight 
structural disparity is endured. Mutagenesis data indicate that one probability about the 
nature of the interaction between the carboxylate moiety of naproxen and mCOX-2 is that 
the carboxylate interacts with Arg-120 via hydrogen bonding rather than ion-pairing 
interactions (Fig.22A). In divergence, the crystal structure of flurbiprofen in complex with 
mCOX-2 shows that the carboxylate makes a salt bridge with the guanidinium group of 
Arg-120.141 Besides, prior studies have revealed a 1000-fold increase in the IC50 value or 
flurbiprofen against R120Q oCOX-1 compared with wild-type enzyme, signifying that ion-
pairing interactions are more vital for inhibition by flurbiprofen than naproxen.145 
The-methyl group of naproxen looks to be involved in key interactions with the COX 
enzymes. Initiation of a range of substituents of variable size and stereochemistry at the 
-position recommends that the steric requirements for this interaction are rigorous, while 
removal of the-methyl group also causes a remarkable loss of potency (Table 3a) The-
methyl group leads to a small hydrophobic cleft below Val-349, which may help to anchor 
naproxen within the mCOX-2 active site and thus strengthen the canonical binding 
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orientation. The x-ray crystal structures of other 2-arylpropionic acids and the diaryl 
heterocyclic compound, SC-558, bound to the COX enzymes direct that the-methyl group 
(or 4-trifluoromethyl, in the case of SC-558) is bound in a similar style to the naproxen 
structure. 131,146 Carboxylate-containing COX inhibitors without a methyl group in the-
position applies alternative interactions to bolster binding within the COX active site. For 
instance, the indolyl-2-methyl group of indomethacin introduces into a hydro-phobic 
pocket above Val-349 lined by Ala-527, Ser-530, and Leu-531 to form a firmly bound 
complex. 131,147 Likewise, whereas diclofenac binds in an inverted orientation with the 
carboxylate coordinated to Ser-530 and Tyr-385, a chlorine atom on the lower aniline ring 
also supplements into the hydrophobic pocket above Val-349. A key interaction between 
naproxen and Trp-387 was revealed during the mutagenesis screen by the indicating that 
the W387F mutant was mostly insensitive to naproxen inhibition. This interaction seems 
to be exclusive to naproxen as the same mutation had no considerable effect on inhibition 
of mCOX-2 by diclofenac, flurbiprofen, or indomethacin (Fig.22B). The interaction with 
Trp-387 may consequence from an amalgamation of hydrophobic packing of the methyl 
group and electro-static interactions with the polarized methoxy group. This area of the 
enzyme looks to be stable in its ability to bind functional groups; the p-hydroxy and p-
ethoxy analogs were very weak inhibitors, however a methylene or sulfur substitution for 
the oxygen atom of the p-methoxy group of naproxen created effective inhibitors of WT 
mCOX-2. Contrasting naproxen, the p-ethyl and p-methyl thio analogs are potent 
inhibitors of W387F mCOX-2. This recommends that either the interaction with Trp-387 
is not essential to inhibition by the naproxen analogs or that they can interact more 
efficiently with W387F COX-2 than is naproxen. Crystal structures of naproxen and the p-
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methyl thio naproxen analog display the substituents at the 6-position oriented in a very 
like fashion at the top of the COX active site, delivering no definitive basis for differential 
inhibition of W387F mCOX-2. Additionally, with the exemption of Leu-352, there are no 
intensely different interactions through the rest of the active site. The substitution of Phe 
for Trp at position 387 generates a larger active site for the mutant enzyme related with 
WT mCOX-2. The capability of the p-ethyl and p-methyl thio naproxen analogs to inhibit 
W387F mCOX-2as well as WT recommends that the analogs may be able to accept an 
alternate conformation in the larger active site of W387F mCOX-2, rewarding for the loss 
of the interaction with Trp-387 in the wild-type enzyme.  
 
1.7.7. Oxicam and its analogs 
 Oxicams are a group of NSAIDs structurally related to 2-methyl-1,2-benzothiazine-
enolamide-1,1-dioxides and different types of substituted oxicams such as meloxicam, 
droxicam and ampiroxicam are available in market. Oxicams are NSAIDs, containing a 
fused thiazine dioxide ring and an extended carboxamide substitution (Fig. 26C).142 The 
oxicam scaffold displays substantial flexibility and occurs as several protonation 
tautomers throughout the keto/enol equilibrium.149 Isoxicam attaches to the COX-2 active 
site using a remarkable binding pose—the murine COX-2isoxicam complex was 
crystallized in the space group P21212 and diffracted to 2.0 Å applying earlier described 





Figure 26. Binding modes of NSAIDs in the COX-2 active site.A,mCOX-2 naproxen complex(PDB ID 3NT1) 
reveals the H-bonding interactions(dashes) between naproxen(yellow) and the constriction site of mcox-2.B, COX-2 
diclofenac complex(PDB ID 1PXX) showing the H-bonding interactions(dashes) between diclofenac(magneta) and Ser-
530 and Tyr-385.C,chemical structure of oxicams and other representative NSAIDs.148 
 
quality to build in significant amounts of COX-2 (residues 33–583) and other protein sub-
structural elements including protoporphyrin IX, the glycosylation sites at Asn-68, Asn-
144, Asn-410, and four -OG detergent molecules after molecular switch and structural 
modification. Four detergent molecules are placed in the outer shell of the protein. There 
are four molecules next to Lys-180 on the side of each monomer, which are shared with 
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four other monomers from symmetric mates, counting as two detergent molecules for 
each asymmetric unit. The other two detergent molecules are outside of Tyr-91 in helix B 
in monomers B and C. No detergent molecules were observed in the lobby region or close 
to helix D. The overall structure, consisted of the epidermal growth factor domain, 
membrane binding domain, and the larger catalytic  
 
Figure 27. Stereo-diagram of the electron density maps around isoxicam and meloxicam. A, a 
simulated annealing composite omit map in the active site of mCOX-2, isoxicam complex. B, a simulated 
annealing composite omit map in the active site of mCOX-2, meloxicam complex. C, a simulated annealing 
composite omit map in the active site of mCOX-1, meloxicam complex. The simulated annealing omits 
maps (34) are contoured at 1.5 in blue mesh; the key residues are illustrated with a stick representation of 
the final modal (carbon in green, oxygen in red, isoxicam in orange); the molecule of isoxicam is colored in 





domain, is like to the high-resolution crystal structure of the mCOX-2 naproxen complex 
(PDB ID 3NT1), and few variations were observed among the four monomers in the 
asymmetric unit with a root mean square deviation from 0.16 to 0.21 Å for the backbone 
atoms. As such, the conformation of isoxicam in monomer A was used to designate the 
facts associated with COX interactions and comparisons with other COX complexes. The 
residues are categorized as the ovine COX-1 numbering system for clarity.131 Well 
classified electron densities accounting for isoxicam were observed in the COX active site 
of all four monomers in one asymmetric unit (Fig. 27A). Isoxicam binds in the COX 
channel in an amazingly unique manner compared with other reported conformation 
between helix 6 and helix 17 in the active site, adjusting a configuration with an 
intramolecular hydrogen bond between the nitrogen atom from the carboxamide and the 
4-hydroxyl oxygen of the benzothiazine. The drug interfaces with the hydrophobic COX 
channel, primarily by van der Waals interactions. The only instant polar interaction 
between isoxicam and COX is a hydrogen bond between the 4-hydroxyl group from 






Figure 28. Isoxicam binds to COX-2 in a novel pose via a two-water-mediated network 
(stereo-diagram). The H-bonds are illustrated as dashes, the key residue is in green sticks, 
water are in deep pink, and isoxicam is in orange.148 
 
Remarkably, two finely ordered water molecules in the active site deliver additional polar 
bridges between isoxicam and COX residues besides the 4-OH–Ser-530 interaction 
(Figs. 27 and 28).148 The first water, which is positioned immediately above the 
constriction site of COX, is approximately 3.0 Å away from both the oxygen of Tyr-355 
and the guanidino nitrogen of Arg- 120, demonstrating that two hydrogen bonds are 
formed. In the meantime, the same water molecule is within H-bond distances of the 
oxygen of the carboxamide and the nitrogen atom in the thiazine ring of the inhibitor. At 
the top of the active site, another water lies between Tyr-385 and Ser-530 and the 
nitrogen atom of the isoxazole ring from isoxicam. The Binding of Isoxicam to COX-2 
takes in Side Chain Rotation of Leu-531 and Structural Movement of Helix D—The 
isoxicam complex discloses a small difference in the backbones of helices C and D in the 
membrane binding domain and the side chain of Leu-531 in helix 17 compared with the 
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1.7 Å resolution mCOX-2naproxen complex (PDB ID 3NT1).148 Because of steric 
hindrance between Val-116 and one oxygen of the dioxide of isoxicam, helix D of COX-2  
 
 
FIGURE 29. Structural changes in helices C and D of COX-2 upon the binding of isoxicam. The backbone atoms 
of monomer A from mCOX-2 naproxen (PDB ID 3NT1) and isoxicam complexes are aligned. The helices are in a tube 
representation, with the naproxen complex in gray and the isoxicam complex in green.148 
 
travels over 1.0 Å to hold the benzyl ring of the benzothiazine without further modifications 
in the orientation of the corresponding residues in the helix (Fig.29). This kind of 
movement was detected in the complexes of COX- 2AA and COX-21-AG (3MDL) but to 
a lesser degree. This accommodation is also found in helix C, which undergoes a 0.5 Å 
shift of the backbone from the original position. This flexibility of membrane binding 
domain helices is steady with the observations made in the complex of human COX-2 
with a zomepirac derivative, RS57067.151 In compare, helix 17, which also co-relates with 
isoxicam, does not move. Though, the side chain of Leu-531 in this helix shows a different 
rotamers (Fig. 30).148 The C atom of Leu-531 shifts approximately 3.5 Å away from the 
active site toward the dimer interface, causing a possible CH- interaction between the C 
atom of Leu-531 and the aromatic ring of the inhibitor with approximately 4.2 Å. This 
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movement releases a new hydrophobic pocket consists of Met-113, Val-116, Leu-117, 
Ile-345, Val-349, Leu-531, Leu-534, and Met-535, which put up the rigid fused benzyl ring 
of isoxicam (Fig. 30). Meloxicam Shows Two Conformations upon Binding to COX-2—
Meloxicam, an analog of isoxicam, is a 5-fold preferential inhibitor of COX-2 over COX-
1.152 To study why meloxicam is a favored COX-2 inhibitor whereas isoxicam is a 
nonselective one, the mCOX-2meloxicam complex was determined by x-ray 
crystallography.The 2.45 Å resolution structure is of appropriate value to include most of 
the components including the EGF domain, membrane binding domain, the catalytic 
domain, and glycosylation sites at Asn-68, Asn-144, and Asn-410. Yet, the detailed 
orientation of the carboxamide moiety of meloxicam could not be determined. Both the 
sulfur and nitrogen atoms of the thiazole ring are good candidates to make an alike 
hydrogen bonding network between the coordinated water and the catalytic apex. The 
electron density around the methyl group on the thiazole ring is inadequate to distinguish 
the conformation in the complex (Fig.27).148 
This statement recommends that two conformations are existing in the m COX-2 
meloxicam complex. In the first conformation, the methyl group points down toward the 
entry of the active site. The nitrogen of the thiazole ring is approximately 2.8 Å away from 
the water, while the sulfur atom interacts with Val-523 and Phe-518 in this conformation. 
In the second conformation, the methyl group points up and binds in a hydrophobic pocket 




FIGURE 30. Leu-531 opens a new binding pocket for isoxicam in the mCOX-2 active site. A, stereo-diagram of 
the surface representation around isoxicam (orange sticks and balls). B, same view of the binding pocket around the 
naproxen (yellow sticks and balls) complex (PDB ID 3NT1). C, binding pocket around 1-AG (yellow sticks and balls) 
complex (PDB ID 3MDL). The interacting residues are in green, and Leu-531 is highlighted in blue; the surrounding 




FIGURE 31. Stereo-diagram of meloxicam bound to the mCOX-2 active site. The protein residues are shown as green sticks 
and balls, the coordinated waters are in spheres, and the methyl-pointing-down conformation of meloxicam is colored in cyan 
and a green dash for the interaction with the water; the methyl-pointing-up conformation is in wheat with the corresponding H-
bond in red. Other hydrogen bonds are illustrated as black dashes.148 
the thiazole group interacts with the water molecule at an effective distance of 3.3 Å.  
Based on the quality of the electron density map or the chemical plausibility for satisfying 
hydrogen bonding and hydrophobic interactions it is not possible to eliminate any 
confirmation. Therefore, both conformations are counted in in the final structure (Fig. 30). 
Other than this conformational flexibility, meloxicam binds to the COX active site in the 
same mode as isoxicam with hydrogen bonding to Ser-530, hydrogen bonding to two 
coordinated waters complexed to Tyr- 385/Ser-530 and Arg-120/Tyr-355, and the new 
hydrophobic pocket generated by the movement of Leu-531. Subtle Structural Features 
around Phe-518 distinct the selectivity of meloxicam for COX-2 over COX-1, Provided 
that New Structural Insights on Selectivity—The structure of ovine COX-1 in complex with 
meloxicam was solved at 2.4 Å resolution. The binding pose of meloxicam in the COX-1 






FIGURE 32. Inhibition of mCOX-2 and mutants by meloxicam. A, inhibition profiles of meloxicam toward oCOX-1, mCOX-2, and 
its mutants. B, structural difference in the active site between oCOX-1 (slate sticks) and mCOX-2 (red sticks) highlighting the 
changes in residues 434, 518, 513, and 523. Points in A are from triplicate measurements and are depicted as the mean S.E. (error 
bars). The backbone atoms of oCOX-1 meloxicam structure are aligned with those of the mCOX-2 meloxicam complex. Only the 
up conformation of meloxicam from mCOX-2 complex is represented for clarity.148 
meloxicam displays an IC50 of 150 nM toward wild-type recombinant mouse COX-2 while 
it shows an IC50 of 990 nM for native ovine COX-1 (Fig. 32), Physically, COX-1 and COX-
2 share most secondary characteristics with slight changes in the active site that include 
I434V, H513R, and I523V COX-13COX-2 substitutions. 131,147 The triple COX-2 mutant of 
V434I/R513H/V523I exhibited a reduced inhibition by meloxicam with an IC50 of 1.22 M, 
which is like wild type ovine COX-1 (Fig. 32). As Arg-513 is placed in the side pocket of 
COX-2 and hardly interacts with meloxicam in the crystal structure, then inhibition studies 
on the mCOX-2 mutants of V434I and V523I was concentrated. The V523I mutant 
displayed potent inhibition by meloxicam with an IC50 of 174 nM. But, meloxicam inhibited 
the V434I mutant with an IC50 of 1.4 M. This study discloses that mutation of Val-434 to 
Ile at position 434 in murine COX-2 is sufficient to decrease the potency of meloxicam 
COX-2 inhibition to that of ovine COX-1 (Fig. 32). The extra carbon in the side chain of 
Ile- 434 in the secondary shell in COX-1 initiates Phe-518 to move toward the main 
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channel further than in COX-2 in which a valine is located at the same position131. 
Therefore, the selectivity of meloxicam for COX-2 is due to the subtle structural features 
about Phe-518, wherever several rotamers of Phe-518 are bestowed in COX-1 and COX-
2 structures because of the difference of secondary shell residues Ile-434 for COX-1 and 
Val-434 for COX-2. 
Oxicams bind in the cyclooxygenase channel with an innovative pose compared with 
earlier described NSAID binding modes, in which the carboxylic acid of the inhibitor 
interacts either in the canonical mode with Arg-120 and Tyr-355131,147 or in the inverted 
binding mode with Tyr-385 and Ser-530.131 On the other hand, oxicams interact with all 
four of these residues, Arg-120, Tyr-355, Tyr-385, and Ser-530. Nevertheless, apart from 
a direct hydrogen bond between the 4-hydroxyl group of the benzothiazine moiety and 
Ser-530, the oxicams do not openly interact with any of these residues by ion pairing or 
hydrogen bonding. But, they interact indirectly by bridging with two tightly bound waters: 
a tetrahedrally coordinated water bound to Arg-120 and Tyr-355 and a trigonally 
coordinated water bound to Tyr-385 and Ser-530. Besides, the water bridge between the 
carboxamide and Ser-530 and Tyr-385 delivers the first structural clarification for the 
study that all oxicam drugs contain a heteroatom at the 1position in the carboxamide 
moiety. The binding of oxicams is go together with by variations in protein conformation, 
explaining an induced fit mechanism, which is unusual in the interaction between COX 
and NSAIDs. This comprises the rotation of the side chain of Leu-531 and a modest 
movement of helix D. The rotamer of Leu-531 in the oxicam complexes is like that 
detected in the nonproductive conformations of mCOX-2AA mCOX-21-AG (36), and 
G533V-AA complexes153, but such a rotation has not been noticed in the binding of any 
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NSAIDs. For isoxicam, it opens a completely new sub-pocket in the COX active site (Fig. 
28), which may characterize a target region for drug discovery. It is an important 
remarking that the variance in orientation of Leu-531 in the complexes of oxicams or 1-
AG is mainly a result of structural fluctuations among the complexes and changes in 
quality of the electron densities around the region in the two complexes. The second 
isoxicam-induced protein conformation is the over 1.0 Å movement of helix D as a retort 
to steric hindrance between the oxygen of the sulfonyl dioxide and the side chain of Val-
116. This extra confirms the flexibility of the membrane-binding domain of COX-2.147 The 
identification of this novel binding approach offers exact interactions between oxicams 
and COX-2 and atonements the prior computational models for oxicams.152 The strain of 
forecasting the oxicam-protein interactions arises for several reasons: the oxicams may 
exist in several tautomers; the two highly coordinated water molecules in the active site 
are nearly impossible to predict, as the representation and role that water plays in ligand-
protein interactions reduces the effective ness of docking predictions154; and the 
recognition  of the movement  of Leu-531 in  COX-2 complexes was only recently 
reported.154 These complex trepidations in the COX-2 active site existing an array of 
computational problems that complicate the forecast of oxicam binding modes. Even 
though most structure-activity relationship studies of oxicams were finished before the 
discovery of COX-2 and before the recognition of the importance of COX-2 in 
inflammation, several lines of sign show that the binding mode labelled here fits well with 
available studies and the pharmacological characterizations of oxicams. The methyl 
substituent at the 2 position of the benzothiazine is optimal for anti-inflammatory activity. 
This methyl group interacts with residues Leu-359, Tyr-355, and Val-349. Replacement 
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of this methyl group with any other substituent (e.g. H, benzyl, allyl, ethyl, propyl) either 
removes the interaction between the protein residues or introduces steric bulk that 
prevents binding in this region. Thus, such substituents were less active than the 2-methyl 
compounds. Among analogs of 3-carboxamides with anilide substituents, meta-
substituted anilides display more potent activity than para-substituted anilides. The meta-
substitution pattern mimics the methyl-up conformation of meloxicam and fits quite well 
within the pocket formed by Leu-384, Tyr-385, Met-522, Phe- 518, and Trp-387 in the 
crystal structures. Finally, in a study of thieno [2,3, -e] thiazine analogs, the 2-pyridyl 
carboxamide (tenoxicam) presented better activity compared with isomeric 3- or 4-pyridyl 
amides, consistent with the essential role of a H-bond acceptor for ligand binding to the 
water coordinated to Tyr-385 and Ser-530. Meloxicam displays modest COX-2 selectivity 
with an IC50 of 150 nM for COX-2 and an IC50 of 990 nM for COX-1 in our in vitro assay. 
In mutagenesis experiments recommend that the preference of meloxicam for COX-2 is 
not because of the substitution of Ile-523 in COX-1 for Val-523 in COX-2, which 
responsible for the selectivity of inhibition by rofecoxib and celecoxib, but somewhat 
subtle changes around Phe-518 produced by the substitution of isoleucine to valine at 
residue 434 in COX-2 (Fig.33). The added methylene group of Ile-434 in oCOX-1 drives 
Phe-518 into the main channel of the cyclooxygenase active site and shrinks the available 
space close to the thiazole ring of meloxicam. This modification of the orientation of Phe-
518 between COX-1 and COX-2 structures was first defined in the complex of COX-2 
with SC-558, a diaryl heterocyclic COX-2 selective inhibitor.131It was recommended that 
the addition of the phenyl sulfonamide group into the side pocket of COX-2 is helped by 
the movement of Phe-518 to accommodate the movement of Val-523. This hypothesis 
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was not verified with mutagenesis experiments. The probable bangs between the 4-
methyl group of meloxicam and Phe-518 propose a direct interaction of Phe-518 with 
inhibitor in the case of meloxicam as resisted to protein movement in the case SC-558. 
Thus, subtle environmental differences around Phe-518 adjust the COX-2 selectivity of 
different classes of inhibitors. Together, the crystal structure of recombinant murine COX-
2 in complex with isoxicam and meloxicam existing here delivers the first structural 
description for the binding mode of the oxicam class of NSAIDs and discloses a novel 
binding mode in the cyclooxygenase channel via a two-water-mediated network 
characterized by interactions with formerly recognized binding residues all over the main 
channel of the active site. Additionally, this binding mode involves the movement of Leu-
531 to accommodate the inhibitor. This is the first time Leu-531 has been known as an 
interacting residue in NSAID binding although it is involved in binding certain substrates. 
Moreover, mutagenesis studies direct that the molecular basis for the preferential 
inhibition of COX-2 by meloxicam is because of the subtle differences around Phe-518 in 
the active site. In conclusion, this structural description of COX-2oxicam complexes 
clarifies previous structure-activity studies of oxicams, directs new substitutions within the 
oxicam scaffold, and finds a new pocket around Leu-531 for development of novel 
NSAIDs. 
 
1.7.8 NSAIDs as anti-cancer agent 
 
Infections and inflammation link to cancer. A possible relation between inflammation and 
the growth of pre-cancerous trauma in different cells have been recognized. The 
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researcher has found that inflammation in prostate, colon, and pancreas will increase 
14%, 25% and 20% risk of prostate, colon and pancreatic cancer respectively.155 
Therefore, inflammation seems to initiate or induce growth of tumor cells. Chronic 
inflammation depicted by infiltration of mononuclear immune cells (including 
macrophages, lymphocytes, and plasma cells), tissue destruction, fibrosis, and increased 
angiogenesis. Due to Chronic inflammation, the initiation and propagation of tumor cells 
such as intensified genomic damage, augmentation of DNA synthesis, cellular 
proliferation, disruption of DNA repair pathways, inhibition of apoptosis, and the promotion 
of angiogenesis and invasion occur in cells. Pro-inflammatory molecules, such as 
cytokines, inducible nitric oxide synthase (iNOS), reactive oxygen species (ROS), and 
NF-kB are upregulated in chronic inflammation. All these processes simultaneously 
ensure a suitable microenvironment for the exponential growth of tumor cells. So, 
inflammation may give both the key mutations and the compatible environment to 
enhance tumor growth.  
In Chavey et al., it is mentioned that some cytokines, including IL-6, IL-8, G-CSF 
(granulocyte colony stimulating factor), IFN-γ (interferon-γ), and MIP-1β (macrophage 
inflammatory protein- 1β), were found to be more abundant in breast carcinoma than in 
normal breast tissue. Nowadays, Researchers also have found that COX1 and COX2 
enzymes are overexpressed in different tumor cells, for example colorectal, gastric, 
esophageal, hepatocellular, pancreatic, head and neck, non-small cell Lung, ovarian, 
breast, bladder, cervical, endometrial and skin Cancer cells.156      
Long term use of aspirin (a Non-selective NSAID) and other NSAIDs reduce the incidence 
of colorectal esophageal, breast, lung and bladder cancers. In 1990, indomethacin was 
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used as an anti-tumor agent in over hundred patients in an advanced stage of colorectal 
cancer and liver, Pancreatic cancer and primary gastric cancers and found that patient 
survived six months more than the expected. Hong-Mei Wang et.al mentioned that 
Indomethacin suppressed the growth of colon cancer via inhibition of angiogenesis in 
vivo.157  
Selective COX-2 inhibitor celecoxib Inhibits AKT signaling and induces apoptosis of 
human colorectal and prostate cancer cells in vitro.158 Researchers also have found that 
COX2 inhibitors also reduce the growth of human breast & lungs cancer and COX1 
inhibitors inhibit the progression of human ovarian as well as colon cancer.  Sue-Lin Fu 
et.al159 have found that COX-2 inhibitors have anticancer effects on gastric cancer. 
Inhibitors show significant roles in angiogenesis and infiltration or metastasis of stomach 
carcinoma. The anticancer effects of COX-2 inhibitors may involve inducing apoptosis, 
suppressing proliferation, reducing angiogenesis and weakening invasiveness. 
Researchers have identified that selective COX-2 inhibitor, Celecoxib active against 
breast cancer in vitro and vivo.160-161 In a combination of NSAIDs and chemotherapeutic 
agents, the scientist has obtained synergetic effects on tumor development and 
progression in vitro models 3. In 1994, Teicher et al. performed a Lewis lung carcinoma 
model and identified a positive effect of using nonsteroidal anti-inflammatory drugs with 
chemotherapy in the primary and last stage of non-small cell lung cancer. It is proven that 
in combinations of a COX inhibitor with chemotherapeutic agents such as cisplatin and 
cyclophosphamide led to tumor growth delay and a decreased number of lung 
metastases.162Moreover, researchers have found a synergistic effect on human NSCLC 
cell lines by using sulindac sulfide (COX-1 and -2 inhibitor) with the cytotoxic agents 
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paclitaxel and docetaxel.163In mouse model study, it is found that non-selective COX 
inhibitor SC-236 drug prevents tumor growth and increases the effect of radiotherapy 
without affecting the radio response of the standard tissue.122Pyro et al. studied and 
identified the radiation-enhancing effect of COX-2 inhibitors in vitro as well as in vivo in 
human lung and colon cancer.164 
COX inhibitor, nimesulide showed inhibition of proliferation and decreased the doses of 
different anti-tumor drugs such as cisplatin, VP-16, and docetaxel.165  
NSAIDs can also use for reduction of side effects associated with chemotherapy.  When 
celecoxib applied with capecitabine for metastatic colorectal cancer chemotherapy, the 
side effects (such as diarrhea and the hand–foot syndrome) decreased in greater 
extent.166 In colorectal cancer xenograft mouse model (HT29 cells and Colon-26 cells in 
nude mice and BALB/c mice) studies, it was found that Celecoxib enhanced CPT-11 
cytotoxicity and also reduced the difficulty of CPT-11 induced diarrhea.167 
Celecoxib increases CPT-11 cytotoxicity in colorectal cancer xenograft mouse models 
(HT29 cells and Colon-26 cells in nude mice and BALB/c mice), but it can also decrease 
the severity of CPT-induced diarrhea. The remission of diarrhea recommends an 
inflammatory part of the pathogenesis of CPT-11 induced delayed diarrhea. Trifan et.al 
identified that COX-2 enzyme was expressed after treatment of rat colon cancer cells with 
CPT-11 and PGE2 synthesis was enhanced.168 
Through cell line model study, it is clear that NSAIDs are also active against the tumor. 
NSAIDs can do prevention of angiogenesis, proliferation, invasive growth, and induce 
apoptosis in cells in a COX2 dependent or independent manner. Anti-cancer activities of 
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NSAIDs follow verities of the mechanism.  But, the key mechanisms are the prevention 
of prostaglandin E2 (PGE2) formation and transcriptional activity of COX2 inhibition. 
Moreover, by clinical trials, the required doses of NSAIDs that induce COX2 free path for 
causing anti-tumor activities are not found yet.  
EGFR (epidermal growth factor receptor) has a significant role in the regulation of normal 
cell growth, apoptosis, and other cellular activities. Different types of cancers such as 
non-small-cell lung cancer, pancreatic cancer, breast cancer, colon cancer and some 
other cancers that are caused by upregulation of EGFR. The receptors are continuously 
and abnormally activated by mutation of EGFRs. EGFR inhibitors used as anti-cancer 
agents. Since COX produces PGE2 which activates the EGFR, in combination therapy 
both inhibitors play a synergetic role in cancer treatment. When Celecoxib was used with 
Herceptin (a monoclonal antibody against the ErbB receptor HER-2/neu) in vitro and in 
the vivo cell proliferation assay, Mann et al. found a positive effect on control of colorectal 
carcinoma cell growth. In colorectal cancer cell growth reduction, COX-2 and HER2/neu 
inhibitors work together more efficiently. In a murine model study of human FAP, it is 
identified that in a combination of sulindac (a COX inhibitor) with EKI-569(an irreversible 
inhibitor of EGFRK) furnish protection to intestinal neoplasia.169  
1.7.9. NSAIDs to circumvent resistance to conventional chemotherapy  
At First, NSAIDs were combined with traditional chemotherapeutic agents to overcome 
cancer chemotherapy resistance mechanism and found that NSAIDs increased the 
efficacy of the chemotherapeutic agents. In the mitochondrial level, Bcl-2 family of pro 
and anti-apoptotic proteins stimulates or inhibits apoptosis. Bcl-2 family members impart 
a clinically important resistance to chemotherapeutic agents in some hematologic and 
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solid malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia, 
chronic myeloid leukemia, chronic lymphoblastic leukemia, multiple myeloma, prostate 
cancer, malignant brain tumors, and neuroblastoma.170-175 Downregulation of Bcl-2 
amplifies toxicity for chemotherapeutic agents in some tumor cell lines.176-177COX-2 
selective NSAIDs such as SC-58125 and NS-398 can down-regulate Bcl-2 and 
consequently induce apoptosis in colon and prostate cancer cell lines.178 In HCT116 
colorectal carcinoma cells, it is found that an increase in pro-apoptotic Bax protein and a 
decrease in Bcl-XL protein induces apoptosis.179 Through Bak and Bax up-regulation, 
mitochondrial membrane potential loss and activation of caspase-3.180-181(Fig-26) 
Celecoxib, aspirin, and indomethacin might induce apoptosis. Bcl-2 family of anti-
apoptosis proteins can also be downregulated by inhibiting Akt signaling. Akt/PKB is a 
serine/threonine protein kinase that works as an important regulator of cell survival and 
proliferation. It has been revealed that PI3K/Akt signaling components are frequently 
altered in human cancers. Another mechanism of amplified Akt signaling is the reduced 
activity of Akt regulatory proteins. Akt phosphorylation is linked with phosphorylation and 
thus inactivation of the pro-apoptotic proteins Bad and caspase-9. Phosphorylated Bad 
cannot bind to Bcl-2, whereas phosphorylated caspase-9 cannot be activated lead to a 
reduced activity of mitochondrial apoptosis182-183. Celecoxib and aspirin inhibit Akt 
phosphorylation and resulting in apoptosis in the human A549 non-small cell lung cancer 
cell line.184 In an in vivo model of spontaneous metastatic breast cancer, it is found that 
celecoxib-induced apoptosis correlated with a significant decrease in Akt activation.185 
Celecoxib also blocked Akt phosphorylation and kinase activity in cultured human C611B 
cholangio carcinoma cells, which associated with Bax translocation to mitochondria, 
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cytochrome c release into the cytosol, followed by activation of caspase-9 and caspase-
3. The addition of PGE2 to these cells suppressed the apoptotic activities of celecoxib.186-
187 The epidermal growth factor receptor (EGFR; erbB1), a member of the tyrosine kinase 
receptor family composed of HER-2/neu (erbB2), erbB3, and erbB4.188-189 The ErbB 
receptors are located at the cell surface and connect to a common structure constituted 
of an extracellular ligand binding domain, the transmembrane segment, and an 
intracellular tyrosine kinase domain.190 When LS-174T colorectal carcinoma cells 
exposed to PGE2 and display rapid induction of Akt signaling, Akt activation can be 
stopped by EGFR-specific tyrosine kinase inhibitors. This rapid transactivation of the 
EGFR appears through an intracellular pathway because inactivation of EGFR ligands 
with inhibitory antibodies did not inhibit PGE2-mediated Akt activation (Fig. 33).191 In 
Caco-2, LoVo and   HT-29   colon   cancer   cell   lines PGE2   expression induces 
phosphorylation and consequently activation of downstream targets of the EGFR pathway 
such as ERK2.When selective inhibitors activated EGFR activation, PGE2 induced ERK2 
activation reduced extensively.192 PGE2, still, can also directly activate EGFR signaling 
and thus promote cell proliferation.190,191 The mechanism involves PGE2-mediated 
metalloproteinase activation resulting in shedding of EGFR ligand from the plasma 
membrane and consequently, stimulated EGFR signaling. Another mechanism includes 
activation of the cAMP/protein kinase A pathway directing to enhanced expression of 
amphiregulin, a ligand of EGFR.193 The TNF family of death receptors and ligands is a 
family of apoptosis-inducing proteins. Several human death receptors have been 
recognized.194,195 Apoptosis is activated upon binding of specific TNF superfamily ligands, 






Figure 33- Akt can be upregulated by COX-2, while both Akt and COX-2 are inhibited by NSAIDs. Inhibition of Akt 
prevents phosphorylation and inactivation of Bad and caspase-9 resulting in decreased apoptosis. Different NSAIDs 
can modulate expression of Bcl-2 family members. Modulation of Bcl-2 family members involves downregulation 
of anti-apoptotic members and upregulation of pro-apoptotic members. 
 
to a receptor TNFR1, TNFR2, Fas or DR4 (TRAIL-R1/APO-2)/DR5 (TRAILR2/ KILLER/ 
TRICK2), respectively. Moreover, attaching to the agonistic receptors TNFR1, TNFR2, 
Fas, DR4, and DR5, FasL can also bind to the soluble inhibitory decoy receptor, DcR3, 
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whereas TRAIL can bind to membrane-bound DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4), 
which both lack functional death domains and are thus unable to induce apoptosis. TRAIL  
also attaches to a soluble TNF family receptor, osteoprotegerin. But, the physiological 
importance of this interaction appears to be nominal. Upon trimerization of the death 
receptors, an intracellular death inducing signaling complex (DISC) is produced that 
consists of trimerized receptor molecules and recruited TNF receptor associated death 
domain (TRADD) or Fas-associated death domain (FADD) and procaspase-8 molecules. 
Subsequent DISC gathering a cascade of effector caspases and substrates are triggered. 
The nucleus is compressed and split, the cytoplasm is reduced, and apoptosis induction 
is completed.196, 197 
Many studies discovered that death receptor apoptosis pathways are involved in 
chemotherapy-induced apoptosis. NSAIDs are also able to induce apoptosis via the 
TRAIL and Fas signaling pathways as was identified by Han et al. They presented that 
FADD is required to induce apoptosis with indomethacin in Jurkat cells.198 Indomethacin 
also induces apoptosis in a developed doxorubicin resistant SCLC cell line via death 
receptor signaling.199 In a hepatocellular cell line model, exposure to NS-398 caused Fas 
ligand upregulation and Fas-mediated apoptosis in COX-2 overexpressing cell lines.200 
TRAIL receptor DR5 was upregulated in colon, prostate, and NSCLC cell lines after 
contact to sulindac sulfide and celecoxib, respectively. These NSAIDs induced apoptosis, 
which was further enlarged in combination with TRAIL201,202 (Fig. 27). COX-2 inhibition 
can be straightway involved in enhancing TRAIL-mediated apoptosis as demonstrated in 
HT29 colon cancer cells. Both COX-2 inhibition and COX-2 downregulation induced 
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clustering of DR5 at the cell surface and reorganization of the death-inducing signaling 
complex components (DR5, FADD, and procaspase-8) into cholesterol-rich and  
ceramide-rich domains.203 Also, the upregulation of DR5, NSAIDs especially, sulindac 
might also increase TRAIL-sensitivity by down-regulating surviving expression.204–207 
Other downstream components of the apoptosis pathway such as anti-apoptotic 
members of the Bcl-2 family can be disturbed NSAIDs as well. For example, the reduction  
 
Figure 34- Death receptor-mediated apoptosis is facilitated at different levels by NSAIDs. NS-398 increases 
FasL expression, sulindac sulfide increases DR5 expression and indomethacin and sulindac sulfide can 
activate the intracellular part of the death-inducing signaling complex. Inhibition of I_B kinases by selective 
and non-selective COX inhibitors results in decreased NF-_B in the nucleus and subsequently in a 
decreased transcription of pro- and anti-apoptosis proteins in expression of the anti-apoptotic protein Bcl-
XL in Bax-proficient HCT116 cells by sulindac sulfide enlarged TRAIL induced apoptosis. The impact of 





1.8 Synthesis of BRL-37959  
 
 BRL-37959 was synthesized by Boyle and his coworkers of using expensive starting 
material and overall yield of the process was only 5%. This synthetic method is shown in 
Scheme 1.  
 
       
Since the compound seemed a potent NSAID, Becham Research Laboratory (BRL) 
developed second method(scheme-2) to produce BRL-37595. The overall yield of the 
method was also ≤ 5%. Then they developed also third method to (scheme-3) synthesize 
the compound but yield was not improved. 
 
1.8.1. Direct Friedel-Crafts benzoylation of 5-chlorobenzofuran-3-ethyl 
ester (3) 
 
Friedel-Crafts benzoylation was done on 5-chlorobenzofuran-3-ethyl ester directly 
(scheme-4) gave benzoylation exclusively at the Ortho-position (i.e., 33) in 20% yield and 
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was not investigated further. This result is supported by previous researchers.217 A long 
with the method above, the method of Sharghi182 et al. was used ZnO as a catalyst 
(Scheme: 5). This process was unsuccessful, and only starting materials were recovered. 
 
 
1.8.2. Attempts to benzoylate 5-chloro salicyalldehyde (1) 
 
 A Fries method was also tested to benzoylate 5-chlorosalicylaldehyde as shown in 
(Scheme 4) below. This method also proved failed when 5-chloro salicylaldehyde was 
used. When only salicylaldehyde was used, the reaction gave low yields (i.e., < 5%) of 
salicylaldehyde benzoylated at the para position. 
 
1.8.3. Exploration of other methods 
 
 
While direct benzoylation of 5-chlorobenzofuran was not feasible due to the above result, 
investigation of previous work, other than that presented earlier, disclosed two interesting 
methods that might have likely in forming the elusive 3-formyl-2-hydroxy benzophenone 
as shown in Figure 35. Synthesis of 3-formyl-hydroxy benzophenone would tolerate for 
subsequent transformation into a benzofuran-3-ethyl ester derivative. Since this 
compound could be proposed through only two possible methods, an approach was made 
to synthesize 3-formyl-2-hydroxybenzophenone. The first method included a novel Mg-
mediated formylation of 2-hydroxybenzophenone and the second method involved either 
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Scheme 6: Fries rearrangement    
                  










Scheme 7: The Duff formylation of salicylic acid 




The second method showed difficult when using the Fries rearrangement and besides 
required protection of the aldehyde functional group. Several protection approaches were 
investigated using salicylaldehyde as the prototypical substrate. Some of these protected 
salicylaldehyde derivatives were tried using diethanolamine, glycol, or methanol to give 
the corresponding acetal or oxazolidine derivatives. Remarkably, the addition of 
diethanolamine to salicylaldehyde gave a high yield (>90%) after azeotropic distillation of 
oxazolidine. Attempted protection with ethylene diamine gave an imine. Furthermore, 
protection of the phenolic group by replacement with methoxy was active using o-
anisaldehyde. In addition to, complete reduction of salicylaldehyde to salicyl alcohol (i.e., 
2-hydroxybenzyl alcohol) was also attempted using sodium borohydride, followed by 
treatment with acetone in the presence of a catalytic amount of aluminum chloride (AICI3). 
This reaction created a protected dioxin compound which subsequently polymerized 
heavily on treatment under the resulting Friedel-Crafts conditions employed 
duringbenzoylation. The overall structures of the protecting groups and the final reaction 
scheme are illustrated in Figure 24 below. None of the protection plans outlined in Figure 









             Figure 36-Protecting group employed in unsuccessful o-benzoylations. 
 
1.8.4. Negative results for acylation at the ortho position. 
 
It seems that there still does not exist a cheap method to produce acylation at the ortho 
position of salicylaldehyde derivatives. Later a review of the literature, only two potential 
literature methods were found. Both procedures were investigated with no positive 







                                                                    
Figure 37- Known literature methods to synthesize 3-formyl-2-hydroxybenzophenones. 
                 Elizalde-Herrera’s method. 
 
                  
Elizalde-Herrera's method is straightforward and inexpensive. It is like the Fries 
rearrangement above. The method seemed to be the same as that did in the Fries 
rearrangement. Discussion with Elizalde himself produced no help in attaining the 
compound. The only proof of benzoylation at the para-position of salicylaldehyde occurs. 
Unfortunately, several attempts at using Elizalde-Herrara's method gave no ortho product 
- only substitution at the para-position. The utility in the investigation of Elizalde-Herrara's 
method ensured to have one positive outcome as it allowed for improvement in yield for 
acylation at the para-position as shown in Scheme 8. 
 
Scheme 8: Improvements upon Elizalde-Herrara's method of p-aroylation of 
Salicylaldehydes 
                  
                                                                                               ~50% 
The method of Dey was, unfortunately, not found to be passable either. Dey's method 
initially looked to be promising, though more complicated and expensive. Dey's process 
was nevertheless, concluded as suitable to produce a valid reference sample for ongoing 
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research. The method needed the use of 3-formyl-salicylic acid from the formylation as 
mentioned earlier procedure of Duff and Bills217 (Scheme 7). Per the method of Kida218 
et. al., 3-Formyl-salicylic acid is then allowed to react in the presence of warm aqueous 
Na2C03 and ethylenediamine in the presence of 1 equivalent Ni(ll) acetate tetrahydrate 
for approximately one hour as shown in Scheme 8. Difficulty rises in this procedure from 
the formation of the highly stable (and unreactive) binuclear complex also shown Scheme 
9. 




                                                            
     










1.8.5 Improved methodology 
 
A developed methodology utilized the use of 2-benzyl-4-chloro-6-formyl-phenol (i.e. 
Chlorophene) as a substrate (Figure 38). This method proved convenient as it completely 
avoids the use of acylation and instead relies on a strategy of benzylic oxidation. The  
Figure 38-Route to BRL37959 showing proposed oxidation 
 
                               
 
 
improved methodology is also cheap and high-yielding, although it is apparently limited 
in comparison to the acylation approach due to the requirement of para-substituted 
phenol derivatives. As shown in Figure 17, the reaction is high-yielding and successful up 
to oxidation of the benzylic carbon. No oxidation was observed at the benzylic carbon 
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despite several strategies using oxidizing methods such as phase transfer catalysis (PTC) 
with NaOH and ambient air (02); NaOCI; H202; and Mn02. 
 
1.8.6. Synthesis of Chiral BRL-37959 
 
In 2012, Bongen, Patrick, and his co-workers synthesized chiral BRL-37959 by direct 
Friedel-Crafts benzoylation of 5-choro benzofuran-3-ethyl ester (scheme- 9) and found 
benzoylation exclusively at the Ortho-position (i.e., 33) in 30% yield. They followed 









Results and Discussion  
2.1. Previous work 
2.1.1. Synthesis of BRL-37959  
 
In 1986, Boyle32 and her co-worker synthesized BRL-37959 (5) and found that the 
compound was active as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The overall 
yield of the method was only 5%(Scheme 9). In the First Step, 6-chloro-4-chromanone 
(1) was treated with thallium trinitrate {Tl(NO3)3} on K-10 clay. Then obtained yellow solid 
was dissolved in MeOH and reacted with Na2CO3 followed by the treatment with EtOH 
and HCl to form Ethyl 5-chloro-benzo[b]furan-3-carboxylate (2) in a 15% yield. In 
reduction, 2 was treated with Mg in MeOH to give methyl 5-chloro-2,3-
dihydrobenzo[b]furan-3-carboxylate (3). Trans-esterification of 3 produced ethyl 5-chloro-
2,3-dihydrobenzo[b]furan-3-carboxylate (4). In benzoylation, 4 was treated with powdered           
 
Scheme 1.  First Method introduced by Boyle et.al to produce BRL 37959. 
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AlCl3 in CS2 at 00C and followed by hydrolysis to give the desired product BRL-37959{7-
Benzoyl- 5-chloro-2,3-dihydrobenzo[b]furan-3-carboxylic acid (5)} and of 34% in yield. 
They did not able to benzoylate 3 and thus one step was increased. The overall yield of 
the synthesis was only < 5%.  
 
Scheme 2. Second Method developed by Boyle et.al to produce BRL -37959. 
 
Since the compound seemed a potent NSAID, Beckham Research Laboratory(BRL) 
developed the second method(scheme-2) to produce BRL-37595. The overall yield of the 
process was also ≤ 5%. The most crucial step is benzoylation reaction(step-8), and yield 
of the step is only 38% that reduced the overall yield. Then they developed also the third 




Scheme 3. Third Method developed by Boyle et.al to produce BRL -37959. 
 
2.1.2. Synthesis of Chiral BRL-37959 
 
In 2012, Bongen, Patrick, and his co-workers synthesized chiral BRL-37959 by direct  
 
Scheme 10. Method introduced by Bongen et.al to make chiral BRL-37959.  
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Friedel-Crafts benzoylation of 5-choro benzofuran-3-ethyl ester (scheme- 12) and found 
benzoylation exclusively at the Ortho-position (i.e., 33) in 30% yield. They followed 
Hossain et al. to synthesize racemic 5-chlorobenzofuran-3-ethyl ester. Bongen, Patrick, 
and his co-workers were not able to solve the problem, i.e., to improve the benzoylation 
step. After benzoylation of (R) methyl 5-chloro-2,3-dihydrobenzo[b]furan-3-carboxylate 
(14) they obtained only trace amount of (R) BRL-37959{7-Benzoyl- 5-chloro-2,3-
dihydrobenzo[b]furan-3-carboxylic acid (15)}. 
 
2.2. Our Contribution. 
2.2.1. Method development for the short synthesis of BRL-37959 
Benzofuran is an essential building block of BRL 37959. In Dr. Hossain's lab, Matt 
Dudley33 had discovered a novel, unique, one-pot procedure to synthesize various 
benzofuran derivatives. We intended to follow the efficient, more cost-effective, large-
scale potential, selective, high yield and simple process to synthesize benzofuran and 
designed a synthetic route (Scheme-11) to synthesize BRL-37959 with higher yield. First 
step is the SN2 and ring   closing reaction of starting material 5-chloro- salicylaldyde 
 





with Ethyl diazo acetate (EDA) and HBF4   at room temperature(RT) to yield Ethyl 5-
chloro-benzo[b]furan-3-carboxylate (2) in 94%33. Next, reduction209-210 of (2) with Mg at 
RT in CH3OH formed Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3-carboxylate (3) in good 
yield of 99%(Scheme 12). 
 
             
 
 
Scheme 12. Preparation of Ethyl 5-chloro-benzo[b]furan-3-carboxylate (2) and   
                        Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (3) 
 
                                 
In Boyle, et al. and Bongen et al. benzoylation of ethyl 5-chloro-2,3-dihydrobenzo[b]furan-
3-carboxylate (4) was done, and yield was 38% and 30% respectively. The major 
challenging step was benzoylation upon which overall yield of the method depended. We 
used up a much of time to improve the benzoylation of (Scheme-15) methyl 5-chloro-2,3 
dihydrobenzo[b]furan-3-carboxylate (3). In benzoylation (step-3), we tried with Lewis Acid 
catalyst AlCl3 along with different solvents and keeping AlCl3, benzoyl chloride, 




                                            
Scheme 13. Friedel-Craft benzoylation of 3. 
 
Next, we decided to keep benzoyl chloride and solvent fixed but vary AlCl3 and 
temperature. Conversion is good,51% of yield in nitromethane at 800C (Table 5. entry 
13).     
Table 4. Effects of solvent. 
 
We attempted to do Friedel-crafts benzoylation reactions without any solvent (Scheme-
16), but the conversion was not good at all (Table 6.). Meanwhile, we found that 
researchers are using microwave radiation211 in organic synthesis for higher yield and 
saving time. Generally, in most organic reactions, traditional heat transfer equipment such 
as oil bath, sand bath, and the heating jacket is used to provide heat to the reaction 
mixture. These heating systems are still rather slow, and temperature gradients can 
develop within the sample. Additionally, local overheating can lead to product, reagent 
and substrate decomposition. In compare, in microwave dielectric heating, the associate 
microwave energy is initiated by the chemical reaction remotely, and direct access to the 
Entry Temperature (0C) Benzoyl 
Chloride 
AlCl3 Solvent Time % of Conversion 
1 50 2 eq 1.2 eq Nitromethane 16h 16 
2 50 2 eq 1.2 eq 1,2-dichloroethane 3-days 0 
3 50 2 eq 1.2 eq Dichloromethane 3-days 2 
4 r.t 2 eq 1.2 eq Carbon disulfide 3-days 8 
9 70 2 eq 1.2 eq Acetonitrile 3-days 0 
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energy sources to the give reaction vessels is obtained. The microwave radiation 
disseminates through the walls of the vessels and heats only reactants and solvents and 
not the reaction vessel itself. If the device is appropriately designed, the temperature 
increase will be even though the sample, which can bring about fewer by-products and 
decomposition products. In pressurized systems, it is likely to fast increase the 
temperature far above the general boiling point of the solvents used. So, we decided to 
apply microwave radiation in our reactions. Before, we optimized AlCl3 loading (1.6 eq.) 
(Table 5. entry 13). In case of microwave-assisted reaction (Scheme 17), we kept solvent 
and catalyst loading fixed, varied benzoyl chloride, temperature as well as time to yield 
67% conversion ((Table 7. entry 6). Next, we attempted to use Zn212 as a catalyst for 
Friedel-craft benzoylation reaction (Scheme 16). 





AlCl3 Solvent Time % of 
Conversion 
1 67 2 eq 1.2 eq Nitromethane 16h No-product 
2 67 2 eq 1.3 eq Nitromethane 24h No-product 
3 67 2 eq 1.4 eq Nitromethane 48h No-product 
4 75 2 eq 1.2 eq Nitromethane 16h No-product 
5 67 2 eq 1.2 eq Dry-Nitromethane 16h 6.33 
6 67 2 eq 1.3eq Distilled 
Nitromethane 
16h 19.5 
7 67 2 eq 1.5eq Distilled 
Nitromethane 
16h 30 
8 60 2 eq 1.5 eq Distilled 
Nitromethane 
16h 19 
9 r.t 2 eq 1.5 eq Distilled 
Nitromethane 
3-days 8 
10 r.t 2 eq 1.5 eq Distilled 
Nitromethane 
10-days 18 
11 70 2 eq 1.5 eq Distilled 
Nitromethane 
16h 39 
12 80 2 eq 1.5 eq Distilled 
Nitromethane 
16h 42 







Scheme 14. Neat benzoylation reaction. 




Scheme 15. Benzoylation reaction with Microwave radiation. 







Entry Temperature (0C) Benzoyl 
Chloride 
AlCl3 Time % of 
Conversion 
1 50 2 eq 1.6 
eq 
3-days 8 
2 70 3 eq 1.6 
eq 
3-days 9 
Entry Temperature (0 C) Benzoyl 
Chloride 
AlCl3 Time % of 
Conversion 
1 75 2 eq 1.6 eq 1h 15 
2 75 3 eq 1.6 eq 1h 30 
3 75 4 eq 1.6 eq 1h 40 
4 75 4.5 eq 1.6 eq 1h 44 
5 75 5.5 eq 1.6 eq 1h 51 
6 80 5.5 eq 1.6 eq 1h 67 
7 90 5.5 eq 1.6 eq 1h 49 
8 80 5.5 eq 1.6 eq 2h 27 
9 100 5.5 eq 1.6 eq 1h 0 
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but the conversion was unsatisfactory. We found that ionic liquids213 is used as an additive 
to increase the catalytic activity of AlCl3 that leads to greater yield. We exploited ionic 
liquid (Scheme 17) and obtained 37% conversion. 
 
                                               
 
Scheme 16. Microwave -assisted benzoylation reaction with Zn catalyst. 
 






Scheme 17. Microwave- assisted reaction with additive. 
 
 




Zn Time % of 
Conversion 
1 100 1 eq 10 eq 10 min 0 
2 140 1 eq 10 eq 30 min 5 
3 140 10 eq 10 eq 1h 10 
4 140 10 eq 10 eq 1h 10 
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Since in benzoylation reaction (Scheme 13), we obtained only 51% conversion, and 
overall yield would not be high, we proposed another route (Scheme 20). We used 5-
chloro-2-hydroxy benzophenone as a starting material to avoid benzoylation (20). We did 
Reimer-Tiemann reaction (Scheme 19) to convert 19 to 7-benzoyl-5-chloro-
salicylaldehyde (20), but unfortunately, no product was formed.  
 
 




Entry Temperature (0C) Benzoyl 
Chloride 
AlCl3 BMIB Time % of 
Conversion 
1 80 14.7 eq 5.40 eq 2.85 eq 1h 37 
2 100 14.7 eq 5.40 eq 3.88 eq 1h 15 
3 100 14.7 eq 5.40 eq - 1h 22 
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Scheme 19.  Reimer-Tiemann reaction of 5-chloro-2-hydroxy benzophenone (20). 







We continuously persuaded to search a suitable catalyst for increasing conversion of 
benzoylation step and found that J.R. Desmur and his co-workers used Bi(OTf)3 catalyst 
in Friedel-Craft benzoylation reaction as well as obtained 80-98% yield214. Next, we 
decided to use the super catalyst in our benzoylation reaction. First, we applied the great 
catalyst in microwave irradiation reaction (Scheme 20). We kept benzoyl chloride, catalyst 
Bi(OTf)3, time fixed and varied temperature and achieved excellent yield of 77% (Table 
11, entry 3)  
 
                                                           
Entry Temperature 
(0 C) 
NaOH CHCl3 Time % of 
Conversion 
1 110 7.5 eq 2 eq 5 min 0 
2 110 7.5 eq 2 eq 10 min 0 
3 120 7.5 eq 6 eq 5 min 0 
4 170 10 eq 30 eq 5 min 0 
5 170 10 eq 30 eq 10 0 
6 90 10 eq 30 eq 1h 0 
7 120 10 eq 30 eq 4h 0 
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Scheme 20. Microwave- assisted reaction with Bi catalyst 
Table 11. Effect of Temperature on Bi(OTf)3 catalyzed Microwave  






Being inspired by the super activity of the catalyst, we planned to utilize Bi(OTf)3 in 
traditional Friedel-Craft benzoylation reaction (Scheme 21). We optimized benzoyl 
chloride, catalyst loading, and temperature to obtain a higher yield of 70%(Table: 12, 
entry 3) 
                                  





Entry Temperature(0C) Benzoyl 
Chloride 




1 100 2.2 eq 0.1 eq 30 min 55 - 
2 120 2.2 eq 0.1 eq 30 min 67 - 
3 140 2.2 eq 0.1 eq 30 min 87 77 
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Scheme 22.  Hydrolysis of Methyl-7-Benzoyl -5-Chloro-2,3-dihydrobenzo [b] furan-3-   
                        carboxylate (15) 
 
Next, hydrolysis of 15 with NaOH in methanol and water at RT (Scheme 22) formed final 
product BRL-37959 (5-chloro-7-benzoyl-2,3-dihdrobenzo[b]furan-3-carboxyllic acid) (5) 
in the great yield of 99%. 
Total Synthesis of BRL-37959:    
 
Entry Temperature (0C) Benzoyl 
Chloride 
Bi(OTf)3 Time % of 
Conversion 
% of Yield 
1 90 0.5 eq 0.1 eq 3 days 64 - 
2 100 0.5 eq 0.1 eq 3 days 59 - 
3 90 2.3 eq 0.2 eq  3 days 87 70 
4 90 2.3 eq 0.2 eq 3 days 90 70 
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2.2.2. Synthesis of analogs of BRL-37959  
 
Now, we developed the methodology of benzoylation reaction; we planned to apply the 
developed method to synthesize some analogs of BRL-37959. First, we intended to make 
Fluoro-analog of BRL-37959 (26) and followed our established synthetic route (Scheme 
25). The step:1 is the SN2   and ring closing reaction33 of starting material 5-Fluoro- 
 
.                          
   
Scheme 23. Proposed synthesis of 7-Benzoyl- 5-Fluoro-2,3-dihydrobenzo[b]furan-3-  
                        carboxylic acid (26)         
 
 
salicylaldyde with Ethyl diazo acetate(EDA) and HBF4 at room temperature (RT) to   yield   
Ethyl 5-Fluoro-benzo[b]furan-3-carboxylate (23) in 74%. Subsequently, reduction209-210 
 
 
Scheme 24. Synthesis of Methyl 5-fluoro-2,3-dihydrobenzo[b]furan-3-carboxylate (24) 
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of (23) with Mg at RT in CH3OH formed Methyl 5-Fluoro-2,3-dihdrobenzo[b]furan-3-
carboxylate (24) in the good yield of 82% (Scheme 24). In microwave-assisted 
benzoylation reaction (Scheme 25) of (24) hold catalyst loading, benzoyl chloride fixed 
and changed temperature as well as time to yield 78% (Table 13, entry 3). After that, we 
focused on typical benzoylation (Scheme 26) of 24. We fixed temperature, time and 
altered catalyst as well as benzoyl chloride to get 50% in yield. (Table 14, entry 3). 
 
Scheme 25. Microwave- assisted reaction with Bi catalyst. 
Table13. Effect of Temperature on Bi(OTf)3 catalyzed Microwave  
                benzoylation reaction 
 




                 
Scheme 26. Conventional benzoylation reaction with Bi catalyst  
Entry Temperature (0C) Benzoyl 
Chloride 
Bi(OTf)3 Time % of Yield 
1 100 2.2 eq 0.1 eq 20 min 45 
2 120 2.2 eq 0.1 eq 30 min 56 
3 140 2.2 eq 0.1 eq 20 min 78 








                                           
 
Scheme 27. Hydrolysis of Methyl-7-Benzoyl -5-Fluoro-2,3-dihydrobenzo 
                     [b] furan-3- carboxylate (26). 
 
Total Synthesis of 5-Fluoro- 7-Benzoyl -2,3-dihydrobenzo 
                        [b] furan-3- carboxylic acid (26) 
 
    
                         
 
Entry Temperature(0C) Benzoyl 
Chloride 
Bi(OTf)3 Time % of 
Yield 
1 90 2.3 eq 0.05 eq 3 days 30 
2 90 2.3 eq 0.1 eq 3 days 50 
3 90 2.3 eq 0.2 eq  3 days 50 
104 
 
Next, we decided to synthesize methyl-analog of BRL-37959 (5-Methyl-7-Benzoyl- 2,3-
dihydrobenzo[b]furan-3-carboxylic acid (31) by following our developed synthetic route 
(Scheme 28).  
                                                                      
Scheme 28. Proposed synthesis of 7-Benzoyl- 5-Methyl-2,3-dihydrobenzo[b]furan-3-  
                         carboxylic acid (31). 
 
The first step is the SN2 and ring closing reaction of starting material 5-Methyl- 
salicylaldyde with Ethyl diazo acetate(EDA) and HBF4 at room temperature (RT) to yield 
Ethyl 5-Methyl-benzo[b]furan-3-carboxylate (28) in 81%33. After that, reduction209-210 of 
(28) with Mg at RT in CH3OH formed Methyl 5-Fluro-2,3-dihdrobenzo[b]furan-3-
carboxylate (29) in a good yield of 91% (Scheme 29).  We pursued   our optimized 
 
                                                   
Scheme 29. Synthesis of Methyl 5-methyl-2,3-dihdrobenzo[b]furan-3- 
                     carboxylate (29) 
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microwave benzoylation reaction (Scheme 30) and formed 30 to yield in 72%(Table15, 
entry 3). Consequently, we augmented traditional Friedel-craft benzoylation (scheme 
30) and achieved 77 % in yield (Table 16, entry 3). 
 
 
Scheme 30. Microwave -assisted reaction with Bi catalyst. 
 





                                         
Scheme 31. Conventional benzoylation reaction with Bi catalyst 
 
 
Entry Temperature(0C) Benzoyl 
Chloride 
Bi(OTf)3 Time % of Yield 
1 100 2.2 eq 0.1 eq 30 min 45 
2 120 2.2 eq 0.1 eq 30 min 60 











                                                           
 
Scheme 32. Hydrolysis of Methyl-7-Benzoyl -5-Methyl-2,3-dihydrobenzo [b] furan-3-    
                    carboxylate (30) 
 
 
Total Synthesis of 7-Benzoyl -5-Methyl-2,3-dihydrobenzo [b] furan-3- 
carboxylic acid (31) 
 
Entry Temperature (0C) Benzoyl 
Chloride 
Bi(OTf)3 Time % of Yield 
1 90 2.3 eq 0.1 eq 3 days 59 
2 100 2.3 eq 0.1 eq 3 days 63 
3 90 2.3 eq 0.15 eq 3 days 67 
4 90 2.3 eq 0.2 eq  3 days 77 
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Afterwards, we designed to prepare methoxy analog of BRL-37959(7-Benzoyl- 5-
Methoxy-2,3-dihydrobenzo[b]furan-3-carboxylic acid) (36) and stuck to our improved 
synthetic route (Scheme 33). The first step is the SN2 and ring closing reaction of starting 
          
            
Scheme 33. Proposed synthesis of 7-Benzoyl- 5-Methoxy-2,3-dihydrobenzo[b]furan-  
                         3-carboxylic acid (36). 
 
material 5-Methoxy- salicylaldyde with Ethyl diazo acetate(EDA) and HBF4 at room 
temperature (RT) to yield Ethyl 5-Methoxy-benzo[b]furan-3-carboxylate (33) in 81%33. 
Next, reduction209-210 of (33) with Mg at RT in CH3OH formed Methyl 5-Methoxy-2,3-
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dihdrobenzo[b]furan-3-carboxylate (34) in a good yield of 91%(Scheme-34). Microwave-
assisted benzoylation reaction (Scheme 35) was carried out with noble catalyst Bi(OTf)3 
to yield 50%(Table 17, entry 4) Subsequently, we kept on our optimized standard Friedel-




                             
Scheme 34. Reduction of Ethyl 5-methyl-benzo[b]furan-3 carboxylate (33)                                      
 
Scheme 35. Microwave -assisted reaction with Bi catalyst. 









Bi(OTf)3 Time % of Yield 
1 100 2.2 eq 0.1 eq 30 min 31 
2 120 2.2 eq 0.1 eq 35 min 36 
3 120 2.2 eq 0.1 eq 30 min 40 
4 140 2.2 eq 0.1 eq 30min 50 




Scheme 36. Traditional benzoylation reaction with Bi catalyst 
 
 




                                              
 
Scheme 37. Hydrolysis of Methyl-7-Benzoyl -5-Methoxy-2,3- dihydrobenzo [b] furan-











Entry Temperature (0C) Benzoyl 
Chloride 
Bi(OTf)3 Time % of Yield 
1 90 2.3 eq 0.1 eq 3 days 50 
2 90 2.3 eq 0.2 eq 3 days 65 
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Total Synthesis of 5-Methoxy 7-Benzoyl --2,3-dihydrobenzo [b] furan-3-   






We performed Molecular Modeling Study of BRL-37959, and p-hydroxy analog of BRL-
37959 {7-(4-hydroxy) Benzoyl- 5-Chloro-2,3-dihydrobenzo[b]furan-3-carboxylic acid} and 
found that both bind with the COX-2 enzyme (Figure- 18,19), but later bind tightly to the 
enzyme. Because of the hydroxyl group in p-hydroxy analog of BRL-37959 forms 
hydrogen bond with amino acid of the COX-2 enzyme. Now, we planned to make more 
analogs by placing different substituents in para-position of benzoyl group in BRL-37959. 
First, we decided to synthesize 7-(4-tri-fluromethyl) Benzoyl- 5-Chloro-2,3-
dihydrobenzo[b]furan-3-carboxylic acid (38). We followed our developed synthetic 




         
 
Scheme 38. Proposed synthesis of 7-(4-tri-fluromethyl) Benzoyl- 5-Chloro-2,3-    




Scheme 39. Microwave -assisted reaction with Bi catalyst 










Bi(OTf)3 Time % of 
Yield 
1 140 1 eq 0.1 eq 20 min 22 
2 140 8.6 eq 0.1 eq 30 min 76 
3 120 7.5 eq 0.1 eq 30 min 70 
4 120 8.6 eq 0.1 eq 1h 79 
5 120 4 eq 0.1 eq 1h 51 
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chloride was treated with 3 and super catalyst Bi(OTf)3 to produce 7-(4-trifluromethyl) 
Benzoyl -5-Chloro-2,3- dihydro benzo [b] furan-3- carboxylate (37) 79% in yield Table 19, 
entry 4). Next, hydrolysis of 37 with NaOH in methanol and water at RT (Scheme 40) 
formed the final product, 7-(4-trifluromethyl) Benzoyl -5-Chloro-2,3-  dihydro benzo [b] 
furan-3-carboxylic acid) (38) in the high yield of 94%. 
 
Scheme 40. Hydrolysis of 7-(4-trifluromethyl) Benzoyl -5-Chloro-2,3- 
                     dihydrobenzo [b] furan-3- carboxylate (38) 
 
Total Synthesis of 7-(4-trifluromethyl) Benzoyl -5-Chloro-2,3-dihydro 








After that, we worked out to make of 7-(4-fluro) Benzoyl- 5-Chloro-2,3-dihydro benzo 
[b]furan-3-carboxylic acid (40) (Scheme 41). We retained catalyst loading, as fixed, varied 
temperature, and benzoyl chloride as well as time in benzoylation (Scheme 42) to yield 
of 48% (Table 18, entry 4). Next, the final product, 7-(4-fluro) benzoyl -5-Chloro-2,3-  
dihydro benzo [b] furan-3-carboxylic acid (40) formed (yield 99%) after hydrolysis of 39 
with NaOH in methanol and water at RT (Scheme-43). 
 
Scheme 41. Proposed synthesis of 7-(4-fluro) Benzoyl- 5-Chloro-2,3-dihydro   
                        benzo[b]furan-3-carboxylic acid (40). 
 
 
Scheme 42. Microwave assisted reaction with Bi catalyst. 
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Scheme 43. Hydrolysis of 7-(4-fluro) Benzoyl -5-Chloro-2,3- dihydrobenzo [b] furan-3-    
                     carboxylate (40). 
 
Thus, Total Synthesis of 7-(4-fluro) Benzoyl -5-Chloro-2,3- 









Bi(OTf)3 Time % of 
Yield 
1 140 8.5 eq 0.1 eq 20 min 38 
2 140 10.8 eq 0.1 eq 1h 48 
3 100 10.8 eq 0.1 eq 1h 45 
4 120 10.8 eq 0.1 eq 1h 48 
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Later, we planned to synthesize 7-(4-chloro) Benzoyl- 5-Chloro-2,3-dihydro benzo[b] 
furan-3-carboxylic acid (42) by following our established synthetic route (Scheme 44). 
We kept benzoyl chloride and time as fixed, but altered catalyst loading and temperature 
in benzoylation reaction (Scheme 45) to form 41 yield in 70% (Table19. entry 6). 
Subsequent, hydrolysis (Scheme 46) we obtained target compound with 99 % in yield. 
Scheme 44. Proposed synthesis of 7-(4-Chloro) Benzoyl- 5-Chloro-2,3- 
                         dihydrobenzo b] furan-3-carboxylic acid (42). 
 
        
    
 
 
                                    












                               
 
Scheme 46. Hydrolysis of 7-(4-Chloro) Benzoyl -5-Chloro-2,3- dihydrobenzo [b] furan-  











Entry Temperature (0C) Benzoyl 
Chloride 
Bi(OTf)3 Time % of Yield 
1 100 2.2 eq 0.2 eq 1h 41 
2 120 2.2 eq 0.2 eq 1h 47 
3 140 2.2 eq 0.2 eq 1h 49 
4 120 2.2 eq 0.3 eq 1h 51 
5 120 2.2 eq 0.3 eq 1h 69 
6 120 2.2 eq 0.3 eq 1h 70 
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Total Synthesis of 7-(4-chloro) Benzoyl -5-Chloro-2,3-  dihydrobenzo[b] 




Next, we decided to make 7-(4-Notro) Benzoyl- 5-Chloro-2,3-dihydro benzo[b] furan-3-
carboxylic acid (44). We did benzoylation reaction by pursuing our established synthetic 
route (Scheme 47) to form 43 (Scheme 48) yield in 56% (Table:20, entry 4).  
          
Scheme 47. Proposed synthesis of 7-(4-Nitro) Benzoyl- 5-Chloro-2,3- dihydrobenzo  








Scheme 48. Microwave-assisted reaction with Bi catalyst 
 






                                
Scheme-49. Hydrolysis of 7-(4-Nitro) Benzoyl -5-Chloro-2,3- dihydrobenzo [b] furan-  






Entry Temperature (0C) Benzoyl 
Chloride 
Bi(OTf)3 Time % of Yield 
1 80 2.2 eq 0.2 eq 1h 43 
2 90 2.2 eq 0.2 eq 1h 46 
3 100 2.2 eq 0.2 eq 1h 53 
4 120 2.2 eq 0.2 eq 1h 56 
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Thus, Total Synthesis of 7-(4-Nitro) Benzoyl -5-Chloro-2,3- 




Afterwards, we designed to the synthesis of 7-(4-Methyl thiol) Benzoyl- 5-Chloro-2,3-
dihydrobenzo[b]furan-3-carboxyllate (45) and stuck to our improved synthetic route  
 
 
Scheme 50. Proposed synthesis of 7-(4-Methyl thiol) Benzoyl- 5-Chloro-2,3- 




(Scheme 50). Microwave-assisted benzoylation reaction (Scheme-51) was carried out 
with great catalyst Bi(OTf)3 to yield 48%(Table:21, entry 4). 
                                  
Scheme 51. Microwave assisted reaction with Bi catalyst 





Next, we planned to synthesis of 7-(4-hydroxy) Benzoyl- 5-Chloro-2,3-dihydro 
benzo[b]furan-3-carboxyllate (47) and followed to our developed synthetic route (Scheme 
51). Microwave-assisted benzoylation reaction (Scheme 56) was carried out with noble 
 
Entry Temperature (0C) 7-(4-Methyl thiol) 
Benzoyl Chloride 
Bi(OTf)3 Time % of Yield 
 
1 100 1 eq 0.2 eq 1h 40 
2 100 2.2 eq 0.2 eq 1h 45 
3 120 2.2 eq 0.2 eq 1h 48 





Scheme 52. Proposed synthesis of 7-(4-hydroxy) Benzoyl- 5-Chloro-2,3-  
                        dihydrobenzo[b]furan-3-carboxyllate (47). 
 
 catalyst Bi(OTf)3, but unfortunately, the reaction did not happen.  
 
 
Scheme-53. Microwave assisted reaction with Bi catalyst 
 
Afterwards, we decided to synthesis of 7-(4-Methyoxy) Benzoyl- 5-Chloro-2,3-




Scheme 54. Proposed synthesis of 7-(4-Methoxy) Benzoyl- 5-Chloro-2,3- dihydrobenzo  
                     [b]furan -3-carboxylic acid (50). 
(Scheme-54). Microwave-assisted benzoylation reaction (Scheme-55) was carried out 
with great catalyst Bi(OTf)3 to yield 45%(Table:22, entry 3). 
 
Scheme-55. Microwave assisted reaction with Bi catalyst. 






Entry Temperature (0C) 7-(4-Methoxy) 
Benzoyl Chloride 
Bi(OTf)3 Time % of Yield 
 
1 90 1 eq 0.2 eq 1h 38 
2 100 2.2 eq 0.2 eq 1h 44 
3 120 2.2 eq 0.2 eq 1h 45 
4 140 2.2 eq 0.2 eq 1h 42 
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2.3. Enzyme Inhibition studies. 
2.3.1. Enzymes 
The expression and purification of murine COX-2 (mCOX-2) from insect cells and of ovine 
COX-1 (oCOX-1) from ram seminal vesicles were done by following published 
methods218-220 All activity or inhibition studies were performed in 100 mM Tris-HCl buffer 
containing 500 µM phenol. Inhibitors were dissolved in dimethyl sulfoxide.  Reaction 
mixtures contained hematin-reconstituted proteins at final enzyme concentrations 
adjusted to give approximately 30-35% substrate consumption (mCOX-2 = 77 nM, oCOX-
1 = 22.5 nM). Fig-18 shows that BRL-37959 is a selective COX-1 inhibitor with IC50 value 
of 245nM.  
Figure-40: Inhibition of puriﬁed Wt mCOX-2 and oCOX-1, by BRL-37959.  
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2.4. Cellular Assays (Proliferation Assay)    
The anti-proliferative activities of the BRL-37959 was verified against colon, breast, 
ovarian and prostate cancer cell lines in an MTT using the Indomethacin as a positive 
control.  The MTT assay is a colorimetric assay for measuring cell viability221. NAD(P)H-
dependent cellular oxidoreductase enzymes indicate the number of viable cells present. 
These enzymes can reduce the tetrazolium dye MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide to its insoluble formazan, which has a purple color. The 
absorbance of this colored solution can be quantified by measuring at a certain 
wavelength (normally between 500 to 600 nm) by a spectrophotometer. The degree of 
light absorption depends on the solvent and how many living cells reduced MTT (yellow) 
to formazan (purple)222. 
 








COL0205(Colon) SKOV-3(Ovarian) MDAMB23(Breast) DV145(Prostate)
% Anti-Proloferation of Cell  by compound  
 80 µM 100 µM 120 µM 140 µM
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3. General Methods and Experimental  
3.1. General considerations   
All reactions were performed under a nitrogen atmosphere in oven-dried glassware with  
magnetic stirring. Air and moisture-sensitive liquids and solutions were transferred via an 
oven-dried, stainless steel syringe and were introduced into the reaction vessel through 
rubber septa. CH2Cl2 was distilled from calcium hydride. Other solvents used were 
distilled from sodium-benzophenone ketyl. Freshly distilled solvents were then degassed 
for Pd-catalyzed reactions by freeze-pump-thaw techniques under vacuum. Previously  
reported compounds were identified by 1H NMR (nuclear magnetic resonance) spectra.   
All new compounds were characterized by additional 13C NMR and high-resolution mass 
spectroscopy. Analytical thin layer chromatography (TLC) was performed on silica gel 
plates (Merck 60F254) visualized either with a UV lamp (254 nm) or by using an iodine  
chamber. Flash chromatography was performed using 40-60 µm silica gel (Silicycle).  
The eluent employed for flash chromatography is reported as volume/volume ratios.  
Organic extracts were dried over anhydrous Na2SO4. The 1H and 13C NMR Spectra were  
performed on a Bruker NMR at 300 and 75 MHz, or 500 and 125 MHz respectively. The1H  
NMR spectral data are reported as follows: chemical shift (δ) in parts per million (ppm) 
from tetramethylsilane as an internal standard (CDCl3 δ7.26 ppm), multiplicity (s = singlet, 




follows: chemical shifts (δ) are reported in parts per million (ppm) from tetramethylsilane  
with the solvent as an internal standard (CDCl3 δ77.16 ppm).  HPCL analysis was115 
performed using a Waters 1500 Series HPLC equipped with a Regis Technologies Pirkle.  
High-resolution mass spectra were done in the MS Shimadzu Laboratory for Advanced 
and Applied Analytical Chemistry at the University of Wisconsin –Milwaukee.  
 
3.2. Experimental Procedures 
 3.2.1.1. Preparation of Ethyl 5-chloro-benzo[b]furan-3-carboxylate33 (2)                                                             
 5-chlorosalicylaldehyde (1g, 6.39 mmol) was added to a 100 mL 3-neck round bottom 
flask fitted with an addition funnel along with 2 mL dichloromethane (DCM). The mixture 
was stirred at room temperature to make a slurry. After this,0.1mL HBF4·OEt2 (0.734 
mmol) was added by a syringe directly to the solution and it was stirred for 15 min for 
protonation of the aldehyde. 2 mL ethyl diazoacetate(EDA) (10.41 mmol) was added to 
the addition funnel along with 1mL DCM. The EDA solution was added dropwise over a 
period of 5-6 hours. The dark yellow colored solution was allowed to stir for 12 hrs. under 
a nitrogen atmosphere. After that, the addition funnel was removed and the reaction 
mixture was concentrated under rotary evaporation to remove free EDA. Then 0.4 mL of 
99.99% H2SO4 was added dropwise to the viscous solution. The round bottom flask was 
placed in an ice-bath and 10 min later the solution was diluted with 2 ml of DCM. The 
acidic reaction mixture was neutralized by adding saturated of NaHCO3 solution. The 
reaction mixture was extracted by DCM. The organic layers were combined and dried 
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over anhydrous Na2SO4 and the solvent was removed by rotovaporation as well as 
yellowish white solid crude product obtained.  
The crude product was dissolved in anhydrous ethanol and 0.183 g NaOH was added. 
The solution was stirred at 380C for 1h. After this, the solution cooled down to room 
temperature and deionized water was added dropwise until no precipitate formed. The 
round bottom flask was placed in an ice-bath for 5-10 minutes and then filtered on a 
Buchner funnel. The off white solid material was allowed to dry on the Buchner Filter for 
1 hr. After that, the material was sublimed under high vacuum and clear white crystals of 
product (99% purity) was obtained.    
1H NMR (300 MHz, CDCl3): δ 8.24(s, 1H), 8.00 (d, 1H), 7.42 (d, 1H), 7.29 (dd, 1H),4.41 
(q, 2H), 1.43 (t, 3H).   




3.2.1.1a. Preparation of Ethyl 5-fluroro-benzo[b]furan-3-carboxylate33 (23)                                                             
 5-Fluorosalicylaldehyde (1g, 7.14 mmol) was added to a 100 mL 3-neck round bottom 
flask fitted with an addition funnel along with 6 mL dichloromethane (DCM). The mixture 
was stirred at r.t. to make a slurry. After this, 0.1mL HBF4·OEt2 (0.735 mmol) was added 
by a syringe directly to the solution and stirred for 15 min for protonation of the aldehyde. 
Then, 1.01 mL ethyl diazoacetate(EDA) (9.55 mmol) was added to the addition funnel 
along with 1mL DCM. The EDA solution was added dropwise over a period of 5-6 hrs. 
The dark yellow colored solution was allowed to stir for 12 hrs. under a nitrogen 
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atmosphere. After that, the addition funnel was removed and the reaction mixture was 
concentrated on a rotary evaporation to remove the remaining EDA. Then 0.5 mL of 
99.99% H2SO4 was added dropwise to the viscous solution. The round bottom flask was 
placed in an ice-bath and 10 min later the solution was diluted with 2 mL of DCM. The 
acidic reaction mixture was neutralized by adding saturated of NaHCO3 solution. The 
reaction mixture was then extracted by DCM. The organic layers were combined and 
dried over anhydrous Na2SO4 and the solvent was removed by rotovaporation and a 
yellowish white colored solid crude product was obtained.  
The crude product was dissolved in anhydrous ethanol and 0.2 g NaOH was added. The 
solution was stirred at 380C for 1h. After this, the solution was cooled down to r.t. and 
deionized water was added dropwise until no precipitate formed. The round bottom flask 
was placed in ice-bath for 5-10 min. and the mixture filtered on a Buchner funnel. The off 
white solid material was allowed to dry on the Buchner filter for 1 hr. After that, the material 
was sublimed under high vacuum and clear white crystals of product (99% purity) was 
obtained. The analytical data matched with previously reported33 data.      
 
3.2.1.1b. Preparation of Methyl 5-methyl-benzo[b]furan-3-carboxylate33 (28)                                                             
 5-methylsalicylaldehyde (1g, 7.34 mmol) was added to a 100 mL 3-neck round bottom 
flask fitted with an addition funnel along with 4 mL dichloromethane (DCM). The mixture 
was stirred at r.t. to make a slurry. After this,0.1mL HBF4·OEt2 (0.734 mmol) was added 
by a syringe directly to the solution and stirred for 15 min for protonation of the aldehyde. 
Then,1.07 mL of Ethyl diazoacetate(EDA) (10.12 mmol) was added to the addition funnel 
along with 2 mL DCM. The EDA solution was added dropwise over a period of 5-6 hrs. 
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The dark yellow colored solution was allowed to stir for 12 hrs. under a nitrogen 
atmosphere. After that, the addition funnel was removed and the reaction mixture was 
concentrated under a rotary evaporatory to remove the remaining EDA. After this,0.4 mL 
of 99.99% H2SO4 was added dropwise to the viscous solution. The round bottom flask 
was placed in an ice-bath and 10 min later the solution was diluted with 2 mL of DCM. 
The acidic reaction mixture was neutralized by adding saturated of NaHCO3 solution. The 
reaction mixture was extracted by DCM. The organic layers were combined and dried 
over anhydrous Na2SO4 and the solvent was removed by rotary evaporation and a 
yellowish white solid crude product was obtained.  
The crude product was dissolved in anhydrous ethanol and 0.2 g NaOH was added. The 
solution was stirred at 380C for 1h. After this, the solution was cooled to r.t. and deionized 
water was added dropwise until no precipitate formed. The round bottom flask was placed 
in an ice-bath for 5-10 min. and filtered on a Buchner funnel. The off white solid material 
allowed to dry on the Buchner filter for 1 hr. After that, the material was sublimed under 
high vacuum and clear white crystals of product (99% purity) was obtained. The analytical 
data matched with previously reported33 data.  
 
3.2.1.1c. Preparation of Ethyl 5-Methoxy-benzo[b]furan-3-carboxylate33 (33) 
    
5-methoxysalicylaldehyde (1g, 6.57 mmol) was added to a 100 mL 3-neck round bottom 
flask fitted with an addition funnel along with 5 mL dichloromethane (DCM). The mixture 
was stirred at r.t. to make a slurry. After this, 0.1mL HBF4·OEt2 (0.734 mmol) was added 
by a syringe directly to the solution and stirred for 15 min for protonation of the aldehyde. 
0.85 mL Ethyl diazoacetate(EDA) (7.80 mmol) was added to the addition funnel along 
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with 1mL DCM. The EDA solution was added dropwise over a period of 5-6 hrs. The dark 
yellow colored solution was allowed to stir for 12 hrs under a nitrogen atmosphere. After 
that, the addition funnel was removed and the reaction mixture was concentrated under 
a rotary evaporatory to remove the remaining EDA. After this,0.4 mL of 99.99% H2SO4 
was added dropwise to the viscous solution. The round bottom flask was placed in an ice-
bath and 10 min later the solution was diluted with 2 mL of DCM. The acidic reaction 
mixture was neutralized by adding saturated of NaHCO3 solution. The reaction mixture 
was extracted by DCM. The organic layers were combined and dried over anhydrous 
Na2SO4 and the solvent was removed by rotary evaporation and a yellowish white solid 
crude product was obtained.  
The crude product was dissolved in anhydrous ethanol and 0.2 g NaOH was added. The 
solution was stirred at 380C for 1h. After this, the solution was cooled to r.t. and deionized 
water was added dropwise until no precipitate formed. The round bottom flask was placed 
in an ice-bath for 5-10 min. and filtered on a Buchner funnel. The off white solid material 
allowed to dry on the Buchner filter for 1 hr. After that, the material was sublimed under 
high vacuum and clear white crystals of product (99% purity) was obtained. The analytical 
data matched with previously reported33 data. 
   
3.2.1.2. Preparation of Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3- 
carboxylate (3) 
 
Ethyl 5-chloro-benzo[b]furan-3-carboxylate (2) (1g, 4.45mmol) was dissolved in 
methanol(35mL) followed by addition of magnesium powder of ~300 mesh (1.2g,0.05 
mol). The reaction mixture was stirred for 3 days under a nitrogen atmosphere at r.t. After 
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that, the reaction mixture was poured to 35 mL of deionized water to quench the reaction 
and ash colored solid material formed. Then, the Erlenmeyer flask containing the reaction 
mixture was placed in an ice bath and 5M HCl was added dropwise until PH   would be 
1.0. The solution was extracted with diethyl ether. The organic layers were combined, 
washed with brine and dried over anhydrous Na2SO4 and the solvent was removed by 
rotary evaporation as well as pale yellow oily product obtained (1.42g, 99% yield).  
1H NMR (300 MHz, CDCl3): δ 7,41(d, J=2Hz,1H), 7.17 (dd, J=8& 2Hz 1H), 6.67 (d, 
J=8Hz,1H), 4.99 -4.37 (m, 3H), 3.82(s,3H).  
3.2.1. 2.a. Methyl 5-Fluoro 2,3-dihdro benzo[b]furan-3-carboxylate (24). 
Ethyl 5-fluoro-benzo[b]furan-3-carboxylate (2) (1.2g, 5.71mmol) was dissolved in 
methanol (20 mL) followed by addition of magnesium powder of ~300 mesh (1.44g,0.06 
mol). After that, the reaction mixture was allowed to stir for 3 days under a nitrogen 
atmosphere at r.t. Then the reaction mixture was poured to 20 mL of deionized water to 
quench the reaction and ash colored solid material was formed. After that, the Erlenmeyer 
flask containing the reaction mixture was placed in an ice bath and 5M HCl was added 
dropwise until PH   would be 1.0. Then, the solution was extracted with diethyl ether. The 
organic layers were combined, washed with brine and dried over anhydrous Na2SO4 and 
the solvent was removed by rotary evaporation and pale yellow oily product was obtained 
(0.90g, 81% yield). The analytical data matched with previously reported33data. 
3.2.1. 2.b. Methyl- 5-Methyl -2,3-dihdro benzo[b]furan-3-carboxylate (29) 
Ethyl 5-methyl-benzo[b]furan-3-carboxylate (2) (1g, 4.85mmol) was dissolved in 
methanol (35mL) followed by addition of magnesium powder of ~300 mesh (1.1g,0.05 
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mol). Then, the reaction mixture was allowed to stir for 3 days under a nitrogen 
atmosphere at r.t. After this, reaction mixture was poured to 35 mL of deionized water to 
quench the reaction and ash colored solid material formed. Then, the Erlenmeyer flask 
containing the reaction mixture was placed in an ice bath and 5M HCl was added 
dropwise until PH   would be 1.0. After that, the solution was extracted with diethyl ether. 
Then, the organic layers were combined, washed with brine and dried over anhydrous 
Na2SO4 and the solvent was removed by rotary evaporation and yellow oily product was 
obtained (0.85g, 91% yield. 
The analytical data matched with previously reported33 data.  
 
3.2.1. 2.c. Methyl- 5-Methoxy -2,3-dihdro benzo[b]furan-3-carboxylate (34). 
Methyl 5-methoxy-benzo[b]furan-3-carboxylate (2) (1g, 4.45mmol) was dissolved in 
methanol (35mL) followed by addition of magnesium powder of ~300 mesh (1.2g,0.058 
mol). Then, the reaction mixture was allowed to stir for 3 days under nitrogen a 
atmosphere at r.t. After this, the reaction mixture was poured to 35 mL of deionized water 
to quench the reaction and ash colored solid material formed. Then, the Erlenmeyer flask 
containing the reaction mixture was placed in an ice bath and 5M HCl was added 
dropwise until PH   would be 1.0. The solution was extracted with diethyl ether. After that, 
the organic layers were combined, washed with brine and dried over anhydrous Na2SO4 
and the solvent was removed by rotovaporation as well as pale yellow oily product 
obtained (0.85g, 92% yield. 
 Analytical data matched with previously reported33data.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
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3.2.1.3. Method A: Synthesis of Methyl-7-benzoyl 5-chloro-2,3-
dihdrobenzo[b]furan-3- carboxylate (15) 
  
AlCl3 (1g.,7.45 mmol) was added to a 100 mL 3-neck round bottom flask fitted with 
condenser and septum connected to a nitrogen line. 10 mL nitromethane was charged 
into the flask. Benzoyl chloride (1 mL,8.79 mmol) was added by a syringe followed by the 
addition of solution of Mthyl-7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate 
(1g.,4.2 mmol, in 10 mL nitromethane). Then, the reaction mixture was heated to 670 C 
with constant stirring for 3 days. Excess nitromethane was removed by rotary evaporator. 
After that, the round bottom flask was placed in an ice-bath and the dark oil residue was 
quenched with concentrated HCl (7 mL) .15 ml of H2O was added to the flask and 
aqueous layer was removed. Then, 15 ml of H2O was added to the flask and extracted 
with 30 mL of CH2Cl2. The organic layers were combined and dried over anhydrous 
Na2SO4 and the solvent was removed by rotovaporation as well as black crude product 
was obtained. 1NMR indicated that roughly 51% of the mixture contained Mthyl-7-benzoyl 
5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (15).  
1H NMR (300 MHz, CDCl3): δ 7.83 (d,J= 5Hz,2H), 7.62(t,J=5Hz,1H), 7.55(S,1H,),7.49( t, 











3.2.1.4 Method B: Microwave-assisted synthesis of Methyl-7-benzoyl 5-
chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (15) 
 
AlCl3 (144 mg., 1.0 mmol) was added to a 10-mL pressurized tube fitted with a magnet 
bar and septum connected to a nitrogen line. Then, benzoyl chloride (0.4 mL,3.75 mmol) 
was added by a syringe followed by the addition of 1mL of nitromethane. After this, the 
reaction was stirred for 20 min and catalyst was dissolved. Then, the solution of Mthyl-7-
benzoyl 5-chloro-2,3-dihdro benzo [b]furan-3- carboxylate (100 mg.,0.47 mmol, in 1 mL 
nitromethane) was added to the tube and quickly septum was removed as well as sealed 
with the high -pressure tolerance septum. After that, the glass tube was placed into a 
CEM microwave at the temperature 800 C, pressure 40 PSI with high steering for 1h. The 
reaction mixture could cool to the room temperature in the MW oven. After cooling, the 
mixture was transferred to the Elamnary flask by CH2Cl2.  The flask was placed in an ice-
bath and the dark oil residue was quenched with concentrated HCl (3 mL). 5 mL of CH2Cl2 
and 5 mL of H2O was added to the flask and aqueous layer was removed. Then, 15 ml of 
H2O was added to the flask and extracted with 30 mL of CH2Cl2. The organic layers were 
combined and dried over anhydrous Na2SO4 and the solvent was removed by 
rotovaporation as well as black crude product obtained. 1NMR indicated that roughly 67% 
of the mixture contained Mthyl-7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3- 
carboxylate (15).  
1H NMR (300 MHz, CDCl3): δ 7.83 (d,J= 5Hz,2H), 7.62(t,J=5Hz,1H), 7.55(S,1H,),7.49( t, 





3.2.1.5 Microwave-assisted synthesis of Methyl-7-benzoyl 5-chloro-2,3-
dihdrobenzo [b]furan-3- carboxylate (15) using Zn and Zn with BMIB (ionic liquid). 
 
 We followed the same procedure of 3.2.1.4. to synthesize Methyl-7-benzoyl 5-chloro-
2,3-dihdrobenzo[b]furan-3- carboxylate (15).   
 
3.2.1.6 Method C: Microwave-assisted synthesis of Methyl-7-benzoyl 5-chloro-2,3- 
dihydro benzo [b] furan-3- carboxylate (15) using Bi(OTf)3 as a catalyst.  
 
 Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) was 
added to a 10mL pressurized glass tube fitted with a septum connected to a nitrogen line. 
Next, Bi(OTf)3 (60 mg,0.046 mmol) was added to the tube followed by the addition of 
1.5mL of nitrobenzene. Benzoyl chloride (0.08 mL,0.01 mmol) was added by a syringe 
and quickly septum was removed as well as sealed with the High -pressure tolerance 
septum. The microtube was placed in the microwave for 1 hour to react at 800 C, 
temperature, 40 PSI pressure with high steering. The reaction mixture was transferred to 
the Elamnary flask. The dark oil residue was quenched with 15 ml of H2O and 10 ml 
CH2Cl2 was added to the flask. Next the solution was passed through the silica plug. The 
filtrate was extracted with 30 mL of CH2Cl2 and organic layer was washed with NaHCO3 
and brine. The organic layers were combined and dried over anhydrous Na2SO4 and the 
solvent was removed by rotovaporation as well as black oily crude product obtained. 
1NMR indicated that roughly 85% of the mixture contained Mthyl-7-benzoyl 5-chloro-2,3-
dihdrobenzo[b]furan-3- carboxylate (15). Next, the crude product was placed on the silica 
plug and washed with hexane followed by washed with ethyl acetate /hexane (5: 95) 
solvent. Nitrobenzene and unreacted starting material was remove. Mixture of product 
and starting material was separated from the silica plug with CH2Cl2 followed by 
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rotovaporation to remove CH2Cl2. After that, Hexane was added to the mixture and heated 
to 700 C and cooled down to RT and crystal of pure product was started to form. This 
crystallization process was repeated for several times and 102 mg (76% yield) of pure 
solid Methyl-7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (15) was 
obtained.   
1H NMR (300 MHz, CDCl3): δ 7.83 (d,J= 5Hz,2H), 7.62(t,J=5Hz,1H), 7.55(S,1H,),7.49( t, 
J=5Hz, 2H), 7.44(S, 1H), 4.99 (t,J=10Hz,1H),4.76(t,J=10Hz,1H),4.40(t,J=10Hz,1H), 
3.86(s,3H).  
 
3.2.1.7 Method D: Traditional synthesis of Methyl-7-benzoyl 5-chloro-2,3- dihydro 
benzo [b] furan-3- carboxylate (15) using Bi(OTf)3 as a catalyst.  
 
 
Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (3) (2.47g,10.44 mmol) was 
added to a 250 mL 3-neck round bottom flask fitted with condenser and septum connected 
to a nitrogen line. Then, Bi(OTf)3 (1.5g, 2.28 mmol) was added to the flask followed by 
the addition of 30 mL of nitrobenzene. After that, benzoyl chloride (2.7 mL,23.24 mmol) 
was added by a syringe. Then, the reaction mixture was heated to 900C with constant 
stirring for 3 days. After that, the reaction mixture was cooled down to r.t. and transferred 
to the Elamnary flask. The dark oil residue was quenched with 50 ml of H2O and 20 ml 
CH2Cl2 was added to the flask. Then, the solution was passed through the silica plug and 
the filtrate was extracted with 250 mL of CH2Cl2 and organic layer was washed with 
NaHCO3 and brine. After this, the organic layers were combined and dried over 
anhydrous Na2SO4 and the solvent was removed by rotovaporation as well as black oily 
crude product obtained. 1NMR indicated that roughly 87% of the mixture contained Mthyl-
7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (15). Then, the crude product 
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was placed on the silica plug and washed with hexane followed by washed with ethyl 
acetate /hexane (5: 95) solvent. Nitrobenzene and unreacted starting material was 
remove. Mixture of product and starting material was separated from the silica plug with 
CH2Cl2 followed by rotovaporation to remove CH2Cl2. After that, Hexane was added to 
the mixture and heated to 700 C and cooled down to RT and crystal of pure product was 
started to form. This crystallization process was repeated for several times and 2.32g 
(70% yield) of pure solid Methyl-7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3- 
carboxylate (15) was obtained. 
1H NMR (300 MHz, CDCl3): δ 7.83 (d,J= 5Hz,2H), 7.62(t,J=5Hz,1H), 7.55(S,1H,),7.49( t, 
J=5Hz, 2H), 7.44(S, 1H), 4.99 (t,J=10Hz,1H),4.76(t,J=10Hz,1H),4.40(t,J=10Hz,1H), 
3.86(s,3H).  
 
3.2.1.8. Preparation of Methyl-7-benzoyl 5-Fluoro-2,3-dihdrobenzo[b]furan-3- 
carboxylate (25): Method C was followed for the preparation of 25. A 10-mL pressurized 
glass tube with High -pressure tolerance septum equipped with a magnet bar was 
charged with Methyl 5-Fluoro-2,3-dihdrobenzo[b]furan-3- carboxylate (24) (0.1g,0.51 
mmol), Bi(OTf)3 (30mg mg,0.046 mmol) and Benzoyl chloride (0.08 mL, 0.1 mmol) in 1 
mL of Nitrobenzene. Then, glass tube was placed into CEM microwave for 1 hr. to react 
at 1400 C, temperature, 40 PSI pressure with high steering. The title compound (0.12 mg, 
78 % of yield) isolated as a solid after crystallization in hexane.  
  For Traditional synthesis of 25 Method D was followed. To a 250 mL 3-neck round 
bottom flask fitted with condenser and septum connected to a nitrogen line was charged 
with Methyl 5-Fluoro-2,3-dihdrobenzo[b]furan-3- carboxylate (24) (2.86g,14.58 mmol), 
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Bi(OTf)3 (1.8g,2.74 mmol), Benzoyl chloride (3.19 mL, 27.46 mmol) and 35 mL of 
Nitrobenzene. Then, the reaction mixture was heated at 900 C with constant steering for 
3-days. The title compound (2.19 g, 50% of yield), was isolated as a solid after 
crystallization in hexane.  
1H NMR (300 MHz, CDCl3): δ 8.10( s,1H),7.80(s,1H),7.59(dd,J=6Hz,2H),7.10(t,J=3Hz, 
1H),6.89(t,J=3Hz,1H),6.76(dd,J=9Hz,1H),4.96 (t,J=10Hz,1H),4.71(t,J=10Hz,1H), 4.35 (t, 
J=10Hz,1H), 3.81(s,3H).  
3.2.1.9. Preparation of Methyl-7-benzoyl 5-Methyl-2,3-dihdrobenzo[b]furan-3- 
carboxylate (30): Method C was followed for the preparation of 30. A 10-mL pressurized 
glass tube with High -pressure tolerance septum equipped with a magnet bar was 
charged with Methyl 5-Methyl-2,3-dihdrobenzo[b]furan-3- carboxylate (29) (0.1g,0.50 
mmol), Bi(OTf)3 (30mg mg,0.046 mmol) and Benzoyl chloride (0.08 mL, 0.10 mmol) in 2 
mL of Nitrobenzene. Then, glass tube was placed into CEM microwave for 1 hour to react 
at 1400 C, temperature, 40 PSI pressure with high steering. The title compound (0.107g, 
72 % of yield) isolated as a solid after crystallization in hexane.  
  For Traditional synthesis of 25 Method D was followed. To a 250 mL 3-neck round 
bottom flask fitted with condenser and septum connected to a nitrogen line was charged 
with Methyl 5-methyl-2,3-dihdrobenzo[b]furan-3- carboxylate (24) (1.2g,6.02 mmol), 
Bi(OTf)3 (0.82g, 1.25 mmol), Benzoyl chloride (1.6 mL, 13.77 mmol) and 25 mL of 
Nitrobenzene. After that, the reaction mixture was heated at 900 C with constant steering 
for 3-days. The title compound (1.37 g, 77% of yield), isolated as a solid after 
crystallization in hexane.  
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 1H NMR(500 MHz, CDCl3):δ 7.81(d,2H),7.58(t,J=9Hz,1H),7.46(t,J=9Hz,2H),7.28(s,2H) 
4.95(dd, J=9Hz,1H), 4.69(t, J=9Hz, 1H), 4.35(t, J=9Hz,1H), 3.82 (s,3H).   
 
3.2.1.10. Preparation of Methyl-7-benzoyl 5-Methoxy-2,3-dihdrobenzo[b]furan-3- 
carboxylate (36): Method C was followed for the preparation of 36. A 10-mL pressurized 
glass tube with Teﬂon-coated septum equipped with a magnet bar was charged with 
Methyl-5-methoxy-2,3-dihdrobenzo[b]furan-3-carboxylate (35) (0.1g,0.48 mmol), Bi(OTf)3 
(30mg mg,0.046 mmol) and Benzoyl chloride (0.12 mL, 1.06 mmol) in 1.0 mL of 
Nitrobenzene. Then, glass tube was placed into CEM microwave for 30 min to react at 
1400 C, temperature, 40 PSI pressure with high steering. The title compound (0.075g, 50 
% of yield) was isolated as a solid after crystallization in hexane.  
  For Traditional synthesis of 36 Method D was followed. To a 250 mL 3-neck round 
bottom flask fitted with condenser and septum connected to a nitrogen line was charged 
with Methyl-5-methoxy-2,3-dihdrobenzo[b]furan-3-carboxylate (35) (1.5g,7.2mmol), 
Bi(OTf)3 (0.94g, 1.43 mmol), Benzoyl chloride (1.8 mL, 15.84 mmol) and 20 mL of 
Nitrobenzene. Then, the reaction mixture was heated at 900 C with constant steering for 
3-days. The title compound (1.46 g, 65% of yield), was isolated as a solid after 
crystallization in hexane.  
1H NMR(500 MHz, CDCl3):δ 7.60(dd,J=2H),7.48 (t,J=9Hz,1H),7.45(t,J=9Hz,2H), 




3.2.1.11. Preparation of 7-(4-tri-fluromethyl) Benzoyl- 5-Chloro-2,3-dihydrobenzo 
[b]furan-3- carboxylate (37): 
Method C was followed for the preparation of 37. A 10-mL pressurized glass tube with 
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3-
dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092 
mmol) and 7-(4-tri-fluromethyl) benzoyl chloride (0.3mL, 2.02 mmol) in 1.0 mL of 
Nitrobenzene. Then, glass tube was placed into CEM microwave for 1hr to react at 1200 
C, temperature, 40 PSI pressure with high steering. The title compound (0.143g, 79 % of 
yield) was isolated as a solid after crystallization in hexane. 
1H NMR (500 MHz, CDCl3): δ 8.02 (d,J=5Hz,1H),7.91(d,J=5Hz, 1H),7.80(dd, J=5hz, 
1H), 7.59(s,1H) 7.48 (s,1H), 7.49(s,1H),7.34(d,J=5Hz,1H)  4.98(t,J=5Hz,1H),4.73(t, 
J=5Hz,1H),4.40(t,J=5Hz,1H), 3.87(s,3H) 
3.2.1.12. Preparation of 7-(4-fluro) Benzoyl- 5-Chloro-2,3-dihydrobenzo [b]furan-3- 
carboxylate (39): 
Method C was followed for the preparation of 39. A 10-mL pressurized glass tube with 
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3-
dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092 
mmol) and 7-(4-fluromethyl) benzoyl chloride (0.3mL, 5.06 mmol) in 1.0 mL of 
Nitrobenzene. Then, glass tube was placed into CEM microwave for 1hr to react at 1200 
C, temperature, 40 PSI pressure with high steering. The title compound (75mg, 48 % of 
yield) was isolated as a solid after crystallization in hexane. 
141 
 
1H NMR(500 MHz, CDCl3):δ 7.78(d,J=10Hz,2H),7.62 (s,1H),7.45(t,J=10Hz,2H), 
7.29(s,2H) 4.99(t,J=5Hz,1H), 4.76(t, J=5Hz, 1H), 4.44(t, J=5Hz,1H), 3.86 (s,3H) 
3.2.1.13. Preparation of 7-(4-Chloro) Benzoyl- 5-Chloro-2,3-dihydrobenzo [b]furan-
3- carboxylate (41): 
Method C was followed for the preparation of 41. A 10-mL pressurized glass tube with 
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3-
dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092 
mmol) and 7-(4-fluromethyl) benzoyl chloride (0.06mL, 0.47 mmol) in 0.5 mL of 
Nitrobenzene. Then, glass tube was placed into CEM microwave for 1hr to react at 1200 
C, temperature, 40 PSI pressure with high steering. The title compound (0.115g, 70 % of 
yield) was isolated as a solid after crystallization in hexane. 
1H NMR(500 MHz, CDCl3):δ 7.77(d,J=9Hz,2H),7.55 (s,1H),7.74(t,J=9Hz,2H), 7.28(s,2H) 
4.98(t,J=15Hz,1H), 4.77(t, J=15Hz, 1H), 4.41(t, J=15Hz,1H), 3.85 (s,3H)   
3.2.1.14. Preparation of 7-(4-Nitro) Benzoyl- 5-Chloro-2,3-dihydrobenzo [b]furan-3- 
carboxylate (43): 
Method C was followed for the preparation of 43. A 10-mL pressurized glass tube with 
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3-
dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092 
mmol) and 7-(4-nitro) benzoyl chloride (0.174g, 0.94 mmol) in 2 mL of Nitrobenzene. 
Then, glass tube was placed into CEM microwave for 1hr to react at 1200 C, temperature, 
40 PSI pressure with high steering. The title compound (86.70mg, 56 % of yield) was 
isolated as a solid after crystallization in hexane. 
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1H NMR (300 MHz, CDCl3): δ 7.86 (s,1H),7.81(dd,J=15Hz,2H)7.40(s,1H), 6.81(d,2H), 
4.93(t,J=6Hz),4.73(t, j=12Hz,1H),4.66(t,1H), 3.89(s,3H).   
 
3.2.1.15. Preparation of 7-(4-Methyl thiol) Benzoyl- 5-Chloro-2,3-dihydrobenzo 
[b]furan-3- carboxylate (45): 
Method C was followed for the preparation of 45. A 10-mL pressurized glass tube with 
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3-
dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092 
mmol) and 7-(4-Methyl thiol) benzoyl chloride (0.16ml, 1.03 mmol) in 2 mL of 
Nitrobenzene. Then, glass tube was placed into CEM microwave for 1hr to react at 1400 
C, temperature, 40 PSI pressure with high steering. The title compound (92.02mg, 54 % 
of yield) was isolated as a solid after crystallization in hexane. 
1H NMR (500MHz, CDCl3):δ 8.35 (s,2H),8.16(d,J=6Hz,2H),7.84(d,J=9Hz,2H), 7.51(dd, 
J=9Hz, 7.44(t,J=2Hz, 1H),4.98(t, J=9Hz,1H), 4.76(t, J=9Hz, 1H),4.16(t,J=9Hz,1H),  3.82 
(s,3H). 
3.2.1.16. Preparation of 5-Chloro -7-Benzoyl -2,3-dihydrobenzo [b] furan-3- 
carboxylic acid (5).  
Methyl-7-Benzoyl- 5-chloro-2,3-dihydro benzo[b]furan-3-carboxylate (15) (1g, 3.15mmol) 
was dissolved in 30mL methanol:H20(1:1) solution followed by addition of sodium 
hydroxide (1.26g,31.5mmol). The reaction mixture was stirred for overnight at RT. 
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30 mL of deionized water was poured to the reaction mixture to quench the reaction and 
the solution was extracted with ethyl acetate. The Erlenmeyer flask containing the 
aqueous layer was placed in an ice bath and 5M HCl was added dropwise until PH   would 
be 1.0. The solution was extracted with ethyl acetate. The organic layers were combined, 
washed with brine and dried over anhydrous Na2SO4 and the solvent was removed by 
rotovaporation as well as pale yellow solid product obtained (0.94g, 99% yield).  
1H NMR (300 MHz, CDCl3): δ 7.84 (d,J= 5Hz,2H), 7.62(t,J=5Hz,2H), 7.51( t, J=5Hz, 
2H), 7.47(S,1H,), 7.29(S, 1H), 4.95(t,J=10Hz,1H),4.78(t,J=10Hz,1H),4.46(t,J=10Hz,1H).   
Analytical data was matched with the previous data33.  
3.2.1.17.a. 5-Fluoro- 7-Benzoyl -2,3-dihydrobenzo [b] furan-3- carboxylic acid (26), 5-
Methyl- 7-Benzoyl -2,3-dihydrobenzo [b] furan-3- carboxylic acid (31), 5-Methoxy 7-
Benzoyl --2,3-dihydrobenzo [b] furan-3- carboxylic acid (36), 7-(4-trifluromethyl) Benzoyl 
-5-Chloro-2,3-dihydro benzo[b] furan-3- carboxylic acid (38), 7-(4-fluro) Benzoyl -5-
Chloro-2,3- dihydrobenzo[b] furan-3- carboxylic acid (41),7-(4-chloro) Benzoyl -5-Chloro-
2,3-  dihydrobenzo[b] furan-3-carboxylic acid (42),7-(4-Nitro) Benzoyl- 5-Chloro-2,3- 
dihydrobenzo [b]furan -3-carboxylic acid (44) were prepared by following procedure in 
3.2.1.16.  
Analytical data:  
5-Fluoro- 7-Benzoyl -2,3-dihydrobenzo [b] furan-3- carboxylic acid (26)  




5-Methyl- 7-Benzoyl -2,3-dihydrobenzo [b] furan-3- carboxylic acid (31) 
1H NMR (300 MHz, CDCl3): δ 7.78(d,J=5Hz,2H), 7.62(t,J=5Hz,2H),7.51(t,J=15Hz ,3H), 
4.86(t,J=10Hz,1H),4.65(t,J=5Hz,1H),4.39(t,J=5Hz,1H). 
7-(4-fluro) Benzoyl -5-Chloro-2,3- dihydrobenzo[b] furan-3- carboxylic acid (41) 
1H NMR (500 MHz, CDCl3): δ 7.78(d,J=10Hz,2H), 7.62(s,J=10Hz,1H),7.49(d,J=10Hz 
,2H), 4.99(t,J=5Hz,1H),4.76(t,J=5Hz,1H),4.44(t,J=5Hz,1H). 
7-(4-chloro) Benzoyl -5-Chloro-2,3-  dihydrobenzo[b] furan-3-carboxylic acid (42). 
1H NMR (500 MHz, CDCl3): δ 7.61(d,J=15Hz ,2H),7.56 (s,1H) ,7.45(t,J=10Hz,2H),7.29 
(s,1H),4.96(t,J=10Hz,1H),4.73(t,J=10Hz,1H),4.40(t,J=10Hz,1H). 
7-(4-trifluromethyl) Benzoyl- 5-Chloro-2,3-dihydrobenzo [b]furan-3- carboxylic acid (38) 
1H NMR (500 MHz, CDCl3): δ 7.78 (d,J=10Hz,1H),7.62(s,1H) 7.48 (s,1H), 7.29(s,1H), 










4. Biological Evaluations. 
4.1. COX Inhibition Screening Assay at Vanderbilt University, Nashville, Tennessee. 
Concentration-dependent inhibition reactions were completed by pre-incubating the 
inhibitor and enzyme for 17 min at 250C, followed by 3 min at 370C prior to the addition of 
50 µM [1-14C]-AA (~55 mCi/mmol, Perkin Elmer, Waltham, MA) for 30 sec. at 370C. 
Reactions were terminated, and the resulting mixtures were analyzed for substrate 
consumption by thin-layer chromatography as previously described194. Inhibitor 
concentrations required for 50% inhibition of enzyme activity (IC50) were determined 
graphically using Prism (GraphPad Software, La Jolla, CA) and were the average of at 
least two independent determinations.   
4.2. Time-Dependent COX Inhibition Assays at Vanderbilt University, Nashville, 
Tennessee. 
 Time-dependent inhibition assays were conducted by pre-incubating increasing 
concentrations of the inhibitor with m/hCOX-2, oCOX-1, or the active site mCOX-2 
mutants for various time points (0, 0.125, 0.25, 0.5, 1, 3, 5, 15, 30 and 60 min) at 370C 
prior to the addition of 50 µM [1-14C]-AA for 30 sec. at 370C.  Reactions were terminated 
and analyzed by thin layer chromatography as described above. The values were the 
average of at least three independent determinations. 
4.3. COX Inhibition Screening Assay by Cayman Chemical, MI. 
 
All reactions were performed in 100 mM Tris (pH 8.0), 5 mM EDTA, 2 mM phenol, and 1 
μM heme. Compounds were diluted in DMSO and incubated with enzyme for 10 minutes 
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at 370C, followed by the initiation of the reaction with 100 μM arachadonic acid. Reactions 
proceed at 370C for 2 minutes, then quenched with 120 mM HCl containing 29 mM 
stannous chloride. SnCl2reduced PGH2 was measured using Cayman Chemical’s 
Prostaglandin Screening ELISA Kit (Item No 514012). The amount of prostaglandin 
product produced from each reaction was calculated using non-linear regression (four-
parameter fit) using Graph Pad Prism V.6.07. Percent inhibition for each compound was 
calculated using the vehicle and inhibited control compound wells. From the studies it is 
found that BRL-37959 and it’s the analogs do not bind with COX-2 enzymes.  
 
 
4.4. Anti-proliferative assay 
The cytotoxicity of the BRL-37959 against the COLO-205 (colon cancer, ATCC), MDA-
MB-231 (breast cancer, ATCC), SKOU-3(ovarian cancer, ATCC), and DU-145 (prostate 
cancer, ATCC), cell lines was tested using the MTT assay as previously described.221, 222  
Concisely, the tumor cells (1x104cells/well) were seeded in 96-well microtiter plates and 
incubated for 24 h at 37ºC. Following incubation, the media was replaced with fresh media 
containing the above compound at concentrations ranging from 1 µM to 1 pM diluted in 
DMSO and incubated for an additional 48 h. Drug was run in duplicate or triplicate and 
control cells received fresh media with DMSO concentration equivalent to the treatment 
groups. Then, the wells were washed twice with warm PBS and incubated for another 4 
h with RPMI 1640 media containing 250 µg/mL of MTT. Later, aspirating the culture 
medium, 200 µL of DMSO was added to dissolve the precipitate and the resulting solution  
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was measured for absorbance at 570 nm with a reference wavelength of 690 nm using a 
microplate reader 56 (Infinite M200 Pro TECAN). Results were used to find out the growth 
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 Analysis of organic compounds using NMR (e.g., 1H, 13C, DEPT, COSY, NOESY, 
HSQC, HMBC etc.), LC-MS, MALDI-TOF, HPLC, FT-IR, GC, UV-visible spectroscopy 
and Polarimetry.   
 
  Well-versed and experienced in the principles of drug design, synthesis, and 
evaluation of biological activity.  
 Scale-up organic reactions on from milligram to kilogram scale, and conduct 
multiple reactions at the same time.  
 
 
 Team builder and motivator. 
 
 Hands-on experience with moisture and air-sensitive reaction techniques.  
 
 Strong written, oral communication and interpersonal skill.   
  
 Computer skills: MS Office, ChemDraw, literature searching via ACS SciFinder 





Ph.D. Organic Chemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53211 
 December ’2017 
 
 
MS, Applied Chemistry & Chemical Technology, University of Dhaka, Bangladesh, 1996  
 
 










September,2009 – Present       Research/Teaching Assistant, Department of Chemistry     
                                                      & Biochemistry, University of Wisconsin- Milwaukee. 
 
 
 Designed and developed a short and effective procedure for the synthesis of 
benzofuran ring containing compound BRL-37959 and its analogs. 
 Designed and discovered that BRL-37959 and its analogs are anticancer drugs. 
 
 Experienced in the design, synthesis, functionalization, characterization and 
biological evaluation of BRL-37959 as a COX1 inhibitor.  
 
 
 Proficient in laboratory techniques, including crystallizations, reagent 
preparation, titrations, spectrophotometric determinations.  
 
 
 Led discussions and lab class for Chemistry: Introductory General Chemistry, 
General Chemistry, Introductory Organic Chemistry & Survey of Biochemistry, 
General Chemistry & Qualitative Analysis, Introductory to Organic Chemistry and 
Organic Chemistry labs. 
 
The main responsibilities in a problem-solving discussion classes and laboratories 
      are:  
 
 Prepare and deliver lectures to students. 
 Evaluate and grade students' class work, laboratory performance, 
assignments, and exam papers. 
 
June,2016 – Augest,2016     Summer Internship (R&D Chemistry), Millipore-Sigma,  
                                                         Milwaukee, Wisconsin. 
 
 
 Scale up multi-steps (5-8 steps) organic synthesis from milligram scale to gram 
scale and run multiple reactions at the same time. 
 Large scale purification process of desired products. 
  Safety and Hazardous training for Industrial R& D  
 Hands on experience of Electronic lab book writing, SOP and ordering chemicals.  
 
2007– 2009                          Shift-In Charge, Mohadevi INC. New York 
  
2004 – 2007                     Assistant Chief, Planning   Commission, Govt. of the People’s Republic    
                                              of Bangladesh.  
 
2001 – 2004                      Assistant Chief, Ministry of Civil Aviation & Tourism, Govt. of the   
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 ‘’ New COX Inhibitors as Anticancer Agents” Shamsul Arefin Ahmed, M. Mahmun 
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 2009-2017.    
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 Member of the American Chemical Society      
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